HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013

DOI: 10.1016/j.hrthm.2013.05.014
Heart Rhythm, 2013, 10, 1932-63.

#	Paper	IF	Citations
1447	A novel pattern of fast calcium oscillations points to calcium and electrical activity cross-talk in rat chromaffin cells. **2005**, 62, 95-104		6
1446	Alzheimer's disease: the impact of age-related changes in reproductive hormones. **2005**, 62, 255-6		6
1445	Familial cardiological and targeted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. *Heart Rhythm*, **2013**, 10, 1653-60	6.7	66
1444	Very prolonged episode of self-terminating ventricular fibrillation in a patient with Brugada syndrome. **2013**, 29, 1742.e1-3		2
1443	Is there a role of MMA T wave alternans test for risk assessment in Brugada syndrome?. **2014**, 14, 96		
1442	Identification of Genetic Alterations, as Causative Genetic Defects in Long QT Syndrome, Using Next Generation Sequencing Technology. **2014**, 9, e114894		23
1441	The Brugada Syndrome - Diagnosis, Clinical Implications and Risk Stratification. **2014**, 9, 82-87		6
1440	Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. **2014**, 7, 1057-63		29
1439	Long QT molecular autopsy in sudden infant death syndrome. **2014**, 99, 635-40		29
1438	Using the electrocardiogram as a crystal ball for cardiovascular and all-cause mortality. **2014**, 35, 1303-5		3
1437	About Brugada phenocopy: Brugada phenocopy with a flecainide overdose: a pharmacological dose effect?. **2014**, 25, E2		2
1436	2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. **2014**, 130, e278-333		272
1435	Comparison of conventional autopsy and magnetic resonance imaging in determining the cause of sudden death in the young. **2014**, 16, 44		35
1434	Common genetic variation and risk for sudden cardiac death in acquired cardiac disease. *Heart Rhythm*, **2014**, 11, 653-4	6.7	1
1433	Type 1 Brugada pattern exacerbation and 1:1 atrioventricular conduction induced by vernakalant. *Heart Rhythm*, **2014**, 11, 895-7	6.7	5
1432	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: validation of the 2013 diagnostic criteria. *Heart Rhythm*, **2014**, 11, 1176-83	6.7	25
1431	Nonsense-mediated mRNA decay due to a CACNA1C splicing mutation in a patient with Brugada syndrome. *Heart Rhythm*, **2014**, 11, 629-34	6.7	20

1430	Electrocardiographic characteristics of premature ventricular contractions in subjects with type 1 pattern of Brugada syndrome. **2014**, 47, 351-5		3
1429	The effect of cardiac genetic testing on psychological well-being and illness perceptions. **2014**, 43, 127-32		9
1428	Early repolarization pattern: its ECG characteristics, arrhythmogeneity and heritability. **2014**, 39, 185-92		13
1427	Brugada syndrome: a review of the literature. **2014**, 14, 482-9		17
1426	Congenital Long QT Syndrome Type 3. **2014**, 6, 705-713		3
1425	Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome. **2014**, 6, 811-817		1
1424	Sodium Current Disorders. **2014**, 6, 825-833		
1423	Near fatal ventricular fibrillation in Brugada syndrome despite presence of an implanted implantable cardioverter defibrillator. **2014**, 30, 1460.e3-5		7
1422	Long-term prognosis in patients with Brugada syndrome based on Class II indication for implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan. *Heart Rhythm*, **2014**, 11, 1716-20	6.7	16
1421	Double trouble, stick to the basics should be the rule!. *Heart Rhythm*, **2014**, 11, 2105-6	6.7	
1420	Rationale and objectives for ECG screening in infancy. *Heart Rhythm*, **2014**, 11, 2316-21	6.7	37
1419	The Role of the Cardiac Sodium Channel in Perinatal Early Infant Mortality. **2014**, 6, 749-759		5
1418	Complex Brugada syndrome inheritance in a family harbouring compound SCN5A and CACNA1C mutations. **2014**, 109, 446		16
1417	Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome. *Heart Rhythm*, **2014**, 11, 1721-7	6.7	12
1416	QT interval is not prolonged in patients with eating disorders. **2014**, 177, 134-5		9
1415	Congenital long QT syndromes: prevalence, pathophysiology and management. **2014**, 16, 447-56		23
1414	Epidemiology of sudden cardiac death in Cameroon: rationale and design of the Douala-SUD survey. **2014**, 107, 433-42		7
1413	2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. **2014**, 64, e77-137		855

1412	Arythmies hŕďitaires associès aux canaux Kv (et autres canaux) cardiaques. **2014**, 2014, 25-30		
1411	Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy. **2014**, 15, 1875-87		8
1410	Intermittent Brugada syndrome in an anorexic adolescent girl. **2014**, 10, 81-84		1
1409	Short QT syndrome: a predictable story. **2014**, 128, 231-3		15
1408	Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?. **2014**, 24, 273-8		18
1407	Catecholaminergic polymorphic ventricular tachycardia (CPVT) initially diagnosed as idiopathic ventricular fibrillation: the importance of thorough diagnostic work-up and follow-up. **2014**, 177, e81-3		5
1406	Life threatening causes of syncope: channelopathies and cardiomyopathies. **2014**, 184, 53-9		3
1405	Cellular quality control: a two-edged sword in Brugada syndrome. *Heart Rhythm*, **2014**, 11, 635-6	6.7	1
1404	PACES/HRS expert consensus statement on the evaluation and management of ventricular arrhythmias in the child with a structurally normal heart. *Heart Rhythm*, **2014**, 11, e55-78	6.7	62
1403	Brugada-type patterns are easily observed in high precordial lead ECGs in collegiate athletes. **2014**, 47, 1-6		27
1402	Remote ICD-monitoring in detection and follow-up of triggers of idiopathic ventricular fibrillation: implications for the clinical management of IVF patients. **2014**, 174, e29-31		3
1401	Management of electrical storm: The mechanism matters. **2014**, 30, 242-249		10
1400	Desmosomes and the sodium channel complex: implications for arrhythmogenic cardiomyopathy and Brugada syndrome. **2014**, 24, 184-90		82
1399	The role of clinical, genetic and segregation evaluation in sudden infant death. **2014**, 242, 9-15		17
1398	Low rate of cardiac events in first-degree relatives of diagnosis-negative young sudden unexplained death syndrome victims during follow-up. *Heart Rhythm*, **2014**, 11, 1728-32	6.7	25
1397	The value of cardiac genetic testing. **2014**, 24, 217-24		29
1396	Sudden death in athletes: preventable or inevitable?. *Heart Rhythm*, **2014**, 11, 1682-3	6.7	2
1395	The role of exercise testing in pediatric cardiology. **2014**, 107, 319-27		27

1394	High prevalence of the SCN5A E1784K mutation in school children with long QT syndrome living on the Okinawa islands. **2014**, 78, 1974-9	16
1393	Never Out of the Woods: Onset of Events in Long QT Syndrome Late in Life Provoked by Atrial Arrhythmias. **2014**, 14, 263-7	1
1392	Sensibilidad y valor predictivo negativo de la ergometrâ para el diagnŠtico de la taquicardia ventricular polimfica catecolaminrgica. **2015**, 68, 545-546	4
1391	The lack of effect of sotalol in short QT syndrome patients carrying the T618I mutation in the gene. **2015**, 1, 373-378	8
1390	Understanding Brugada syndrome. **2015**, 28, 32-6	3
1389	Channelopathies - emerging trends in the management of inherited arrhythmias. **2015**, 15, 43-54	5
1388	Risk stratification in patients with Brugada syndrome without previous cardiac arrest prognostic value of combined risk factors. **2015**, 79, 310-7	50
1387	Long-term prognosis of early repolarization with J-wave and QRS slur patterns on the resting electrocardiogram: a cohort study. **2015**, 163, 747-55	20
1386	Determining the pathogenicity of genetic variants associated with cardiac channelopathies. **2015**, 5, 7953	37
1385	An update on early repolarization(ER) syndrome. **2015**, 15, 265-7	
1384	Choking-induced cardiac arrest unmasks a diagnosis of catecholaminergic polymorphic ventricular tachycardia. **2015**, 1, 494-497	
1383	The Reply. **2015**, 128, e35	
1382	Symptoms Before Sudden Arrhythmic Death Syndrome: A Nationwide Study Among the Young in Denmark. **2015**, 26, 761-7	18
1381	The Prognostic Value of Early Repolarization with ST-Segment Elevation by Age and Gender in the Hispanic Population. **2015**, 38, 1396-404	4
1380	Fever-Induced Brugada Syndrome. **2015**, 3, 2324709615577414	5
1379	Reassuring News for Genetically Tested, Appropriately Treated, Low-Risk LQTS Patients. **2015**, 26, 859-861	
1378	A Shocking End to the Defibrillator as We Know It: Unmet Needs and the Case for a Stand-Alone Device that Uses Pacing Only to Treat the Risk of Life-Threatening Arrhythmias. **2015**, 38, 655-8	1
1377	Relationship between J Waves and Vagal Activity in Patients Who Do Not Have Structural Heart Disease. **2015**, 20, 464-73	6

1376	Genetics of inherited arrhythmias in pediatrics. **2015**, 27, 665-74		8
1375	Over the Counter Drugs and Long QT Syndrome: Near Lethal Syncope after Cold Relief by Phenylephrine. **2015**, 5,		
1374	Next Generation Sequencing: The Current Challenge is the Translation into Clinics. **2015**, 02,		
1373	Genetics of inherited primary arrhythmia disorders. **2015**, 8, 215-33		14
1372	Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome. **2015**, 10, e0133037		32
1371	Management of Patients with Inherited Primary Arrhythmia Syndromes. **2015**, 35, 77-85		
1370	Brugada syndrome and its relevance in the perioperative period. **2015**, 18, 403-13		8
1369	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. **2015**, 36, 1290-6		144
1368	Impact of sex and ethnicity on arrhythmic risk. **2015**, 17, 604		5
1367	Sensitivity and negative predictive value of treadmill exercise stress testing for the diagnosis of catecholaminergic polymorphic ventricular tachycardia. **2015**, 68, 545-6		
1366	Sensitivity and negative predictive value of treadmill exercise stress testing for the diagnosis of catecholaminergic polymorphic ventricular tachycardia. Response. **2015**, 68, 546-7		
1365	Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. **2015**, 116, 1989-2004		54
1364	Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application. **2015**, 13, 769-82		4
1363	Genetics of sudden cardiac death. **2015**, 116, 1919-36		161
1362	The spectrum of epidemiology underlying sudden cardiac death. **2015**, 116, 1887-906		296
1361	Sympathectomy for Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: Should We Have the Nerve?. **2015**, 131, 2169-71		4
1360	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. **2015**, 131, 2185-93		174
1359	Everybody has Brugada syndrome until proven otherwise?. *Heart Rhythm*, **2015**, 12, 1595-8	6.7	30

1358	Brugada ECG patterns in athletes. **2015**, 48, 539-43	8
1357	A tick-borne illness unmasking asymptomatic Brugada syndrome. **2015**, 2015, 191-3	1
1356	A 26-year-old competitive soccer player with syncope. **2015**, 187, 1225-1228	
1355	Influence of Gender on the Tolerability, Safety, and Efficacy of Quinidine Used for Treatment of Supraventricular and Ventricular Arrhythmias. **2015**, 116, 1845-51	19
1354	Clinical presentation and course of long QT syndrome in Thai children. **2015**, 31, 296-301	4
1353	Trastornos del ritmo y de la conducci□n en el ni□. **2015**, 50, 1-13	
1352	Left Cardiac Sympathetic Denervation: Should We Sweat the Side Effects?. **2015**, 8, 1007-9	4
1351	Quinidine in Brugada Syndrome: Still a Long Way to Go□**2015**, 8, 1309-10	6
1350	[ESC guidelines 2015 for ventricular arrhythmias and prevention of sudden cardiac death. What is new?]. **2015**, 40, 1034-42	0
1349	The association of J wave and ventricular tachycardia before device implantation with device interventions for ventricular tachyarrhythmia. **2015**, 48, 721-8	1
1348	Use of whole exome sequencing for the identification of Ito-based arrhythmia mechanism and therapy. **2015**, 4,	13
1347	Long QT Syndrome and Sports Participation: Oil and Water or an Acceptable and Manageable Combination?. **2015**, 1, 71-73	8
1346	Mexiletine Prevents Recurrent Torsades´de´Pointes in Acquired Long´QT´Syndrome Refractory to Conventional Measures. **2015**, 1, 315-322	38
1345	Clinical aspects of inherited J-wave syndromes. **2015**, 25, 24-30	8
1344	A new mutation in the ryanodine receptor 2 gene (RYR2 C2277R) as a cause catecholaminergic polymorphic ventricular tachycardia. **2015**, 68, 71-3	3
1343	Adherence to the Mediterranean diet in patients with coronary artery disease. **2015**, 68, 73-5	3
1342	J-wave syndrome(s). **2015**, 25, 22-3	1
1341	High-dose flecainide with low-dose □blocker therapy in catecholaminergic polymorphic ventricular tachycardia: A case report and review of the literature. **2015**, 11, 10-13	6

1340	Una nueva mutaci□n en el gen del receptor de la rianodina (RyR2 C2277R) como causa de taquicardia ventricular polim□rfica catecolamin□rgica. **2015**, 68, 71-73		8
1339	Next-generation sequencing for the diagnosis of cardiac arrhythmia syndromes. *Heart Rhythm*, **2015**, 12, 1062-70	6.7	23
1338	Hereditary Arrhythmias. **2015**, 167-190		
1337	Characteristics of "malignant" vs. "benign" electrocardiographic patterns of early repolarization. **2015**, 48, 390-4		14
1336	Risk factors and causes of sudden noncardiac death: A nationwide cohort study in Denmark. *Heart Rhythm*, **2015**, 12, 968-74	6.7	20
1335	Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome. **2015**, 65, 151-9		46
1334	Programmed electrical stimulation for patients with asymptomatic Brugada syndrome? The shock-filled debate continues. **2015**, 65, 889-91		5
1333	QT interval variations and mortality risk: is there any relationship?. **2015**, 15, 255-8		8
1332	Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no effect on the QT interval. **2015**, 36, 2523-9		45
1331	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. **2015**, 33, 17-24		17
1330	A viewpoint on monitoring strategies in a patient with Bruguda Syndrome. A commentary by Dr Andreas Vogt. **2015**, 5, 114-115		
1329	Sensibilidad y valor predictivo negativo de la ergometr□a para el diagn□stico de la taquicardia ventricular polim□rfica catecolamin□rgica. Respuesta. **2015**, 68, 546-547		
1328	Ankyrin-2 variants associated with idiopathic ventricular fibrillation storm in patients with intermittent early repolarization pattern. **2015**, 1, 337-341		5
1327	Massive parallel sequencing applied to the molecular autopsy in sudden cardiac death in the young. **2015**, 18, 160-70		25
1326	Increased Tpeak-Tend interval is highly and independently related to arrhythmic events in Brugada syndrome. *Heart Rhythm*, **2015**, 12, 2469-76	6.7	62
1325	Meta-Analysis on Risk Stratification of Asymptomatic Individuals With the Brugada Phenotype. **2015**, 116, 98-103		34
1324	Something Old, Something New: Using Family History and Genetic Testing to Diagnose and Manage Athletes with Inherited Cardiovascular Disease. **2015**, 34, 517-37		4
1323	Catecholaminergic polymorphic ventricular tachycardia: disease with different faces. **2015**, 8, 523-5		1

1322	Characterization of repolarization in Brugada syndrome patients during exercise testing: Dynamic angle evaluation. **2015**, 48, 879-86		2
1321	Athletes with Implantable Cardioverter Defibrillators. **2015**, 34, 473-87		5
1320	Use of genetic testing to identify sudden cardiac death syndromes. **2015**, 25, 738-48		9
1319	Gene therapy to treat cardiac arrhythmias. **2015**, 12, 531-46		27
1318	Relationships between the QTc interval and cardiovascular, stroke, or sudden cardiac mortality in the general Japanese population. **2015**, 65, 237-42		13
1317	Prognostic value of programmed electrical stimulation in Brugada syndrome: 20 years experience. **2015**, 8, 777-84		78
1316	Brugada syndrome in children. **2015**, 13, 173-81		4
1315	Homozygous/Compound Heterozygous Triadin Mutations Associated With Autosomal-Recessive Long-QT Syndrome and Pediatric Sudden Cardiac Arrest: Elucidation of the Triadin Knockout Syndrome. **2015**, 131, 2051-60		74
1314	Brugada syndrome unmasked by ischemia needs full risk evaluation: author's reply. **2015**, 10, 113		
1313	Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. **2015**, 8, 633-42		141
1312	Rare Incidence of Ventricular Tachycardia and Torsades de Pointes in Hospitalized Patients With Prolonged QT Who Later Received Levofloxacin: A Retrospective Study. **2015**, 90, 606-12		9
1311	The use of noninvasive ECG imaging for examination of a patient with Brugada syndrome. **2015**, 1, 260-263		3
1310	Strain Echocardiography and LQTS´Subtypes: Mechanical Alterations in an Electrical Disorder. **2015**, 8, 511-513		3
1309	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. **2015**, 190, 393-402		43
1308	Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2015**, 12, 1636-43	6.7	31
1307	Sudden cardiac death. **2015**, 40, 133-200		64
1306	Controversies in arrhythmias and arrhythmic syndromes of active children and young adults. **2015**, 13, 183-92		1
1305	A practical guide to early repolarization. **2015**, 30, 8-16		9

1304	Benefit of implantable cardioverter-defibrillator therapy after generator replacement in patients with Brugada syndrome. **2015**, 187, 340-4	6
1303	Inherited progressive cardiac conduction disorders. **2015**, 30, 33-9	50
1302	Cardiac channelopathies in pediatric patients - 7-years single center experience. **2015**, 48, 150-6	3
1301	Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. **2015**, 68, 861-8	2
1300	Catecholaminergic polymorphic ventricular tachycardia: a rare cause of recurrent syncope. **2015**, 2015, 337-42	
1299	[Brugada ECG]. **2015**, 26, 247-59	
1298	Asymptomatic Brugada Syndrome: Clinical Characterization and Long-Term Prognosis. **2015**, 8, 1144-50	57
1297	Ventricular fibrillation in lone atrial fibrillation as clinical manifestation of latent Brugada syndrome: Usefulness of flecainide testing. **2015**, 1, 285-289	2
1296	Fenotipo heterogĥeo del sn̂drome de QT largo causado por la mutaciñ KCNH2-H562R: importancia del estudio gentico familiar. **2015**, 68, 861-868	5
1295	Getting to the heart of hERG K(+) channel gating. **2015**, 593, 2575-85	19
1294	Evaluation of the necessity for cardioverter-defibrillator implantation in elderly patients with Brugada syndrome. **2015**, 8, 785-91	28
1293	Short QT and atrial fibrillation: A mutation-specific disease. Late follow-up in three unrelated children. **2015**, 1, 193-197	10
1292	Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. **2015**, 8, 1373-81	155
1291	Update on the Diagnosis and Management of Brugada Syndrome. **2015**, 24, 1141-8	25
1290	Clinical Cardiac Electrophysiology in the Young. **2015**,	
1289	Follow-up of 316 molecularly defined pediatric long-QT syndrome patients: clinical course, treatments, and side effects. **2015**, 8, 815-23	17
1288	[The ECG of athletes]. **2015**, 26, 274-90	2
1287	A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. **2015**, 107, 613-23	46

1286	Broad-based molecular autopsy: a potential tool to investigate the involvement of subtle cardiac conditions in sudden unexpected death in infancy and early childhood. **2015**, 100, 952-6		22
1285	Seasonal, weekly, and circadian distribution of ventricular fibrillation in patients with J-wave syndrome from the J-PREVENT registry. **2015**, 31, 268-73		6
1284	Role of pharmacotherapy in cardiac ion channelopathies. **2015**, 155, 132-42		22
1283	Coronary artery fistulas and Brugada ECG pattern, a random association?. **2015**, 197, 78-80		9
1282	Atrial and ventricular tachyarrhythmias in military personnel. **2015**, 161, 244-52		4
1281	A refined protocol of flecainide testing in Brugada syndrome: from ambiguous assessment toward definite diagnosis. *Heart Rhythm*, **2015**, 12, 358-9	6.7	
1280	Clinical Cardiac Electrophysiology in Clinical Practice. **2015**,		
1279	Must every child with long QT syndrome take a beta blocker?. **2015**, 100, 279-82		11
1278	Separation of benign from malignant J waves. *Heart Rhythm*, **2015**, 12, 384-5	6.7	13
1277	Electrocardiographic methods for diagnosis and risk stratification in the Brugada syndrome. **2015**, 27, 96-108		14
1276	History and clinical significance of early repolarization syndrome. *Heart Rhythm*, **2015**, 12, 242-9	6.7	26
1275	Genetics of sudden cardiac death in the young. **2015**, 88, 101-13		10
1274	Ryanodine Receptor Channelopathies in Skeletal and Cardiac Muscle. **2016**, 53-84		1
1273	Tachyarrhythmia Cycle Length in Appropriate versus Inappropriate Defibrillator Shocks in Brugada Syndrome, Early Repolarization Syndrome, or Idiopathic Ventricular Fibrillation. **2016**, 46, 179-85		3
1272	A Clinical Perspective on Sudden Cardiac Death. **2016**, 5, 177-182		31
1271	Brugada Syndrome: Defining the Risk in Asymptomatic Patients. **2016**, 5, 164-169		9
1270	J Wave Syndromes: History and Current Controversies. **2016**, 46, 601-609		8
1269	Management of Patients with Long QT Syndrome. **2016**, 46, 747-752		13

1268	The Brugada Syndrome: A Rare Arrhythmia Disorder with Complex Inheritance. **2016**, 3, 9	39
1267	Next-Generation Sequencing in Post-mortem Genetic Testing of Young Sudden Cardiac Death Cases. **2016**, 3, 13	13
1266	Challenges in Molecular Diagnostics of Channelopathies in the Next-Generation Sequencing Era: Less Is More?. **2016**, 3, 29	4
1265	Diagnosis, Treatment, and Mechanisms of Long QT Syndrome. **2016**, 113-130	3
1264	The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. **2016**, 5, 45-9	13
1263	Complexity of Molecular Genetics in the Inherited Cardiac Arrhythmias. **2016**, 345-368	1
1262	Catecholaminergic Polymorphic Ventricular Tachycardia in Pregnancy. **2016**, 127, 735-739	6
1261	Brugada syndrome: diagnosis, risk stratification, and management. **2016**, 31, 37-45	15
1260	Chloride channel dysfunction study in myotonic dystrophy type 1 using repeated short exercise tests. **2016**, 54, 104-9	
1259	Brugada Syndrome Diagnosed from the ECG Leads in the High Intercostal Spaces: Searching for Answers from a Higher Source?. **2016**, 27, 944-6	3
1258	Factors influencing uptake of familial long QT syndrome genetic testing. **2016**, 170A, 418-425	31
1257	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. **2016**, 27, 937-43	14
1256	Syncope and Early Repolarization: A Benign or Dangerous ECG Finding?. **2016**, 1, 179-186	
1255	Fever-Induced Brugada Syndrome Is More Common Than Previously Suspected: A Cross-Sectional Study from an Endemic Area. **2016**, 21, 136-41	28
1254	Effect of Left Cardiac Sympathetic Denervation on the Electromechanical Window in Patients with either Type 1 or Type 2 Long QT Syndrome: A Pilot Study. **2016**, 11, 437-443	6
1253	Electrocardiographic features of sudden unexpected death in epilepsy. **2016**, 57, e135-9	25
1252	Exercise and Arrhythmias: A Double-Edged Sword. **2016**, 39, 748-62	10
1251	Management of survivors of cardiac arrest - the importance of genetic investigation. **2016**, 13, 560-6	9

1250	Implantable cardioverter defibrillator therapy in young patients with cardiomyopathies and channelopathies: a single Italian centre experience. **2016**, 17, 485-93		9
1249	Genetic Testing for Cardiovascular Conditions Predisposing to Sudden Death. **2016**, 175-186		1
1248	Long QT Syndrome. **2016**, 287-302		
1247	Catecholaminergic Polymorphic Ventricular Tachycardia. **2016**, 324-330		
1246	New Insights Into the Genetic Basis of Inherited Arrhythmia Syndromes. **2016**, 9, 569-577		29
1245	Guâ ESC 2016 sobre el diagnÊtico y tratamiento de la insuficiencia cardiaca aguda y crñica. **2016**, 69, 1167.e1-1167.e85		91
1244	Current Cardiovascular Genetic Counseling. **2016**, 4, 142-146		
1243	Electrocardiographic screening of children and adolescents: the search for hidden risk. **2016**, 37, 2498-501		2
1242	Impact of Updated Diagnostic Criteria for´Long QT Syndrome on Clinical Detection of´Diseased Patients: Results From a Study of Patients Carrying Gene Mutations. **2016**, 2, 279-287		5
1241	Catheter Ablation of Recurrent Ventricular Fibrillation: A Literature Review and Case Examples. **2016**, 25, 784-90		3
1240	Effect of flecainide on suppression of ventricular fibrillation in a patient with early repolarization syndrome. *Heart Rhythm*, **2016**, 13, 1724-8	6.7	4
1239	Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias. **2016**, 32, 340-343		16
1238	Sudden cardiac death: A reappraisal. **2016**, 26, 709-719		7
1237	The evolution of sports participation guidelines and the influence of genotype-phenotype correlation in long QT syndrome. **2016**, 26, 690-697		4
1236	Reply: Search for Evidence-Based Medicine for Brugada Syndrome: The Complex Network of the Brugada Syndrome. **2016**, 67, 1658-1659		1
1235	Intoxication with alcohol: An underestimated trigger of Brugada syndrome?. **2016**, 7, 2054270416640153		11
1234	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. **2016**, 37, 2129-2200		7751
1233	Cardiac Delayed Rectifier Potassium Channels in Health and Disease. **2016**, 8, 307-22		30

1232	Iron Overload Leading to Torsades de Pointes in Thalassemia and Long QT Syndrome. **2016**, 8, 247-56		2
1231	Arrhythmias: Opening Pandora's Box -- incidental genetic findings. **2016**, 13, 187-8		
1230	Probability of diagnosing long QT syndrome in children and adolescents according to the criteria of the HRS/EHRA/APHRS expert consensus statement. **2016**, 37, 2490-7		14
1229	Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart Association. **2016**, 133, 1520-9		67
1228	Molecular autopsy in victims of inherited arrhythmias. **2016**, 32, 359-365		26
1227	Rare Disease and Low Event Rates: Challenges for Refining Risk Stratification in Brugada Syndrome. **2016**, 32, 1294.e1-1294.e3		1
1226	Ventricular fibrillation: triggers, mechanisms and therapies. **2016**, 12, 373-90		10
1225	Brugada syndrome - Case report, risk stratification and treatment. **2016**, 58, e491-e496		4
1224	Idiopathic Ventricular Fibrillation: The Struggle for Definition, Diagnosis, and Follow-Up. **2016**, 9,		38
1223	A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2016**, 13, 1652-60	6.7	43
1222	Short QT Syndrome in Current Clinical Practice. **2016**, 24, 190-3		5
1221	Catheter ablation for ventricular tachyarrhythmia in patients with channelopathies. **2016**, 32, 404-410		5
1220	Genetics of Brugada syndrome. **2016**, 32, 418-425		57
1219	Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. **2016**, 9, 448-467		37
1218	Sudden Cardiac Death in Athletes: Still Much to Learn. **2016**, 34, 531-541		3
1217	Inhibitory effects of hesperetin on Nav1.5 channels stably expressed in HEK 293 cells and on the voltage-gated cardiac sodium current in human atrial myocytes. **2016**, 37, 1563-1573		3
1216	Early somatic mosaicism is a rare cause of long-QT syndrome. **2016**, 113, 11555-11560		30
1215	Corrected QT interval anomalies are associated with worse prognosis among patients suffering from sepsis. **2016**, 46, 1204-1211		8

1214	Quinidine for Brugada syndrome: Panacea or poison?. **2016**, 2, 486-490	1
1213	Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. *Heart Rhythm*, **2016**, 13, 2395-2398	6.7
1212	A patient with early repolarization syndrome and concurrent Brugada syndrome: Demonstration of a different pathophysiology?. **2016**, 223, 58-60	1
1211	Role of Genetic Testing in Patients with Ventricular Arrhythmias in Apparently Normal Hearts. **2016**, 8, 515-23	0
1210	Polymorphic Ventricular Tachycardia/Ventricular Fibrillation and Sudden Cardiac Death in the Normal Heart. **2016**, 8, 581-91	6
1209	Exercise-induced Ventricular Tachycardia/Ventricular Fibrillation in the Normal Heart: Risk Stratification and Management. **2016**, 8, 593-600	3
1208	12-Lead electrocardiogram as a predictor of sudden cardiac death: from epidemiology to clinical practice. **2016**, 50, 253-259	3
1207	Letter by Jim□nez-J□mez and Tercedor S□chez Regarding Article, "Outcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registry". **2016**, 9, e003984	1
1206	Where There's Smoke, There's Fire? Significance of Atrial Fibrillation in Young Patients. **2016**, 39, 229-33	5
1205	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. **2016**, 18, 891-975	4036
1204	Nonsustained Ventricular Tachycardia in the Normal Heart: Risk Stratification and Management. **2016**, 8, 525-43	8
1203	Use of a subcutaneous ICD in a patient with short QT syndrome. **2016**, 4, 35-8	9
1202	Experience with bisoprolol in long-QT1 and long-QT2 syndrome. **2016**, 47, 163-170	21
1201	Trouble du rythme et de la conduction chez l□nfant. **2016**, 29, 191-210	1
1200	Exercise and □blocker therapy recommendations for inherited arrhythmogenic conditions. **2016**, 26, 1123-9	5
1199	Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. **2016**, 8, 361-72	3
1198	Pronounced Shortening of QT Interval With Mexiletine Infusion Test in Patients With Type 3 Congenital Long QT Syndrome. **2016**, 80, 340-5	25
1197	Activation Pattern of the Polymorphic Ventricular Tachycardia and Ventricular Fibrillation on Body Surface Mapping in Patients With Brugada Syndrome. **2016**, 80, 1734-43	2

1196	Catecholaminergic Polymorphic Ventricular Tachycardia. **2016**, 80, 1285-91		54
1195	Prevalence and Clinical Impact of Early Repolarization Pattern and QRS-Fragmentation in High-Risk Patients With Brugada Syndrome. **2016**, 80, 2109-16		16
1194	Pathogenesis and management of Brugada syndrome. **2016**, 13, 744-756		62
1193	Cardiac Abnormalities in First-Degree Relatives of Unexplained Cardiac Arrest Victims: A Report From the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry. **2016**, 9,		30
1192	Risk stratification of ventricular fibrillation in Brugada syndrome using noninvasive scoring methods. *Heart Rhythm*, **2016**, 13, 1947-54	6.7	29
1191	Reply to the Editor-Brugada syndrome is not an ECG. *Heart Rhythm*, **2016**, 13, e292	6.7	1
1190	Basic Cardiac Electrophysiology and Common Drug-induced Arrhythmias. **2016**, 28, 357-71		6
1189	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. **2017**, 19, 665-694		127
1188	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Heart Rhythm*, **2016**, 13, e295-324	6.7	166
1187	Long-Term Outcome of Patients Initially Diagnosed With Idiopathic Ventricular Fibrillation: A Descriptive Study. **2016**, 9,		28
1186	Channelopathies: Literacy´and´Competence. **2016**, 2, 400-401		
1185	Management of Brugada Syndrome 2016: Should All High Risk Patients Receive an ICD? All High-Risk Patients Should Receive an Implantable Cardiac Defibrillator. **2016**, 9,		9
1184	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. **2016**, 32, 315-339		90
1183	The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most. **2016**,		61
1182	Ventricular Tachycardia. **2016**, 233-265		
1181	Idiopathisches Kammerflimmern wie behandeln?. **2016**, 5, 255-259		
1180	A meta-analytic review of prevalence for Brugada ECG patterns and the risk for death. **2016**, 95, e5643		26
1179	Risk of sudden death in subjects with Brugada type 1 electrocardiographic pattern and no previous cardiac arrest: is it high enough to justify an extensive use of prophylactic ICD?. **2016**, 17, 408-10		3

1178	Appearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome. **2016**, 2, 407-411	2
1177	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. **2016**, 25, 2093-2103	20
1176	Whole-Exome Molecular Autopsy After Exertion-Related Sudden Unexplained Death in the Young. **2016**, 9, 259-65	56
1175	Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center's Early Experience. **2016**, 2, 253-262	24
1174	Catecholaminergic Polymorphic Ventricular Tachycardia: Activity as Tolerated?. **2016**, 2, 263-265	
1173	A Prospective Study of Sudden Cardiac Death among Children and Young Adults. **2016**, 374, 2441-52	396
1172	Predictors of Ventricular Arrhythmias and Sudden Death in a Qubec Cohort With Brugada Syndrome. **2016**, 32, 1355.e1-1355.e7	15
1171	Clinical and genetic features of Australian families with long QT syndrome: A registry-based study. **2016**, 32, 456-461	7
1170	La importancia del estudio familiar y gentico: la mutacin p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. **2016**, 69, 702-704	1
1169	Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?. **2016**, 5, 211-6	17
1168	Repeated molecular genetic analysis in Brugada syndrome revealed a novel disease-associated large deletion in the SCN5A gene. **2016**, 2, 261-264	2
1167	Reporte de un caso de fibrilacin auricular como manifestacin inicial de sndrome de Brugada. **2016**, 23, 301.e1-301.e5	1
1166	Founder Mutation Genotyping and Sudden Cardiac Arrest: The Promise of Precision Medicine Fulfilled or the Next Step Into Precise Uncertainty. **2016**, 9, 107-9	1
1165	Molecular pathogenesis of long QT syndrome type 2. **2016**, 32, 373-380	52
1164	Recent advances in genetic testing and counseling for inherited arrhythmias. **2016**, 32, 389-397	24
1163	Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. **2016**, 26, 647-53	38
1162	ST elevation without cardio-pulmonary symptoms. **2016**, 32, 239-40	
1161	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. **2016**, 69, 702-4	

1160	Dysfunction of the Voltage-Gated K+ Channel Subunit in a Familial Case of Brugada Syndrome. **2016**, 5,		15
1159	Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. **2016**, 594, 3911-54		131
1158	J Wave Syndromes. **2016**,		
1157	Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management. **2016**, 175, 1235-1248		52
1156	Ten advances defining sudden cardiac death. **2016**, 26, 23-33		16
1155	Sudden Cardiac Arrest and Rare Genetic Variants in the Community. **2016**, 9, 147-53		22
1154	Primary prevention of idiopathic ventricular fibrillation: Not for the faint of heart. *Heart Rhythm*, **2016**, 13, 913-4	6.7	1
1153	Criteria for evaluating rSr' patterns due to high precordial ECG lead placement accurately confirm absence of a Brugada ECG pattern. **2016**, 49, 182-6		3
1152	Shocking numbers--Reeducation to reduce inappropriate ICD utilization for congenital long QT syndrome. *Heart Rhythm*, **2016**, 13, 886-7	6.7	1
1151	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. **2016**, 133, 622-30		138
1150	Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation. **2016**, 39, 647-59		18
1149	Risk Stratification in Brugada Syndrome: The "Impossible" Made Possible?. **2016**, 67, 1441-1443		2
1148	Electro-mechanical dysfunction in long QT syndrome: Role for arrhythmogenic risk prediction and modulation by sex and sex hormones. **2016**, 120, 255-69		21
1147	Postmortem genetic analysis of sudden unexplained death syndrome under 50 years of age: A next-generation sequencing study. *Heart Rhythm*, **2016**, 13, 1544-51	6.7	26
1146	Prognostic significance of fever-induced Brugada syndrome. *Heart Rhythm*, **2016**, 13, 1515-20	6.7	46
1145	Teenage pregnancy with catecholaminergic polymorphic ventricular tachycardia and documented ICD discharges. **2016**, 4, 361-5		13
1144	A novel mutation in the SCN5A gene contributes to arrhythmogenic characteristics of early repolarization syndrome. **2016**, 37, 727-33		10
1143	Early Repolarization in Athletes: A Review. **2016**, 9, e003577		16

1142	Prevalence of Microvolt T-Wave Alternans in Patients With Long QT Syndrome and Its Association With Torsade de Pointes. **2016**, 9, e003206		28
1141	A Case for Inclusion of Genetic Counselors in Cardiac Care. **2016**, 24, 49-55		26
1140	Evaluation of syncope: focus on diagnosis and treatment of neurally mediated syncope. **2016**, 14, 725-36		10
1139	Ion Channel Diseases: an Update for 2016. **2016**, 18, 21		3
1138	Brugada Syndrome. **2016**, 8, 239-45		3
1137	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. *Heart Rhythm*, **2016**, 13, 1274-82	6.7	71
1136	Effect of verapamil in the treatment of type 2 long QT syndrome is not a dose-dependent pattern: a study from bedside to bench, and back. **2016**, 18, A37-A46		2
1135	Sudden Cardiac Death in the Young. **2016**, 133, 1006-26		66
1134	Update on the Diagnosis and Management of Familial Long QT Syndrome. **2016**, 25, 769-76		25
1133	Implantable cardioverter-defibrillator explantation for overdiagnosed or overtreated congenital long QT syndrome. *Heart Rhythm*, **2016**, 13, 879-85	6.7	29
1132	Expanding the genetic counseling workforce: program directors' views on increasing the size of genetic counseling graduate programs. **2016**, 18, 842-9		41
1131	Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of Eblockade. *Heart Rhythm*, **2016**, 13, 609-13	6.7	41
1130	A Tale of 2 Diseases: The History of Long-QT Syndrome and Brugada Syndrome. **2016**, 67, 100-8		34
1129	Interpretation of the Electrocardiogram in Athletes. **2016**, 32, 438-51		13
1128	The Arrhythmic Patient in the Emergency Department. **2016**,		
1127	Beta-blockers in the treatment of catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2016**, 13, 441-2	6.7	7
1126	Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current. **2016**, 9, e003436		6
1125	Genetic testing and genetic counseling in patients with sudden death risk due to heritable arrhythmias. *Heart Rhythm*, **2016**, 13, 789-97	6.7	25

1124	Syncopal Event During a Soccer Game. **2016**, 55, 387-9		
1123	The prevalence and significance of a short QT interval in 18,825 low-risk individuals including athletes. **2016**, 50, 124-9		60
1122	Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with 1-selective blockers in patients with catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2016**, 13, 433-40	6.7	61
1121	Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study. *Heart Rhythm*, **2016**, 13, 669-82	6.7	56
1120	The Osborn wave: what have we learned?. **2016**, 41, 48-56		7
1119	Risk stratification in Brugada syndrome: Clinical characteristics, electrocardiographic parameters, and auxiliary testing. *Heart Rhythm*, **2016**, 13, 299-310	6.7	65
1118	Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome. **2016**, 37, 630-7		17
1117	Genetics of long-QT syndrome. **2016**, 61, 51-5		99
1116	The role of genetic testing in unexplained sudden death. **2016**, 168, 59-73		23
1115	Management of an asymptomatic patient with dynamically changing J wave from inferior early repolarization to Brugada pattern. *Heart Rhythm*, **2016**, 13, 565-8	6.7	2
1114	Genetic screening in sudden cardiac death in the young can save future lives. **2016**, 130, 59-66		44
1113	Utility of T-wave alternans during night time as a predictor for ventricular fibrillation in patients with Brugada syndrome. **2016**, 31, 947-56		16
1112	Brugada syndrome: clinical and genetic findings. **2016**, 18, 3-12		73
1111	Clinical Characteristics and Long-Term Prognosis of Senior Patients With Brugada Syndrome. **2017**, 3, 57-67		9
1110	Brugada Syndrome Unmasked by Heat Exhaustion. **2017**, 22,		10
1109	Gender differences in sudden cardiac death in the young-a nationwide study. **2017**, 17, 19		33
1108	Genetic Insurance Discrimination in Sudden Arrhythmia Death Syndromes: Empirical Evidence From a Cross-Sectional Survey in North America. **2017**, 10,		12
1107	Brugada syndrome: Diagnosis, risk stratification and management. **2017**, 110, 188-195		35

1106	Sports participation in long QT syndrome. **2017**, 27, S43-S48		5
1105	Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. **2017**, 27, S49-S56		4
1104	Next-generation sequencing of a large gene panel in patients initially diagnosed with idiopathic ventricular fibrillation. *Heart Rhythm*, **2017**, 14, 1035-1040	6.7	15
1103	How to develop a clinic for sudden cardiac arrest survivors and families of non-survivors. **2017**, 27, S3-S9		6
1102	Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes. **2017**, 27, S126-S131		6
1101	Athletic participation in the young patient with an implantable cardioverter-defibrillator. **2017**, 27, S132-S137		1
1100	A novel method to enhance phenotype, epicardial functional substrates, and ventricular tachyarrhythmias in Brugada syndrome. *Heart Rhythm*, **2017**, 14, 508-517	6.7	29
1099	Brugada syndrome and calcium channel mutation in a patient with congenital deaf mutism. **2017**, 17, 16-17		
1098	International Recommendations for Electrocardiographic Interpretation in´Athletes. **2017**, 69, 1057-1075		171
1097	Exercise-induced syncope in a 22-year-old man. **2017**, 103, 642		2
1096	CSE database: extended annotations and new recommendations for ECG software testing. **2017**, 55, 1473-1482		11
1095	Fever vs drug: Battling with the Brugada syndrome substrate. *Heart Rhythm*, **2017**, 14, 518-519	6.7	2
1094	Heart Rhythm Society: expert consensus statements-part 1. **2017**, 40, 177-185		1
1093	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*, **2017**, 14, e155-e217	6.7	74
1092	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2017**, 70, e39-e110		154
1091	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2017**, 136, e60-e122		137
1090	At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease. **2017**, 26, 669-688		3
1089	Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations. **2017**, 103, 901-909		13

1088	A Rhythm Revealed: Transient Brugada Pattern. **2017**, 130, 542-544		
1087	Evaluation of Prolonged QT Interval: Structural Heart Disease Mimicking Long QT Syndrome. **2017**, 40, 417-424		4
1086	Causes of sudden death in the young Cardiac and non-cardiac. **2017**, 45, 2-13		1
1085	International criteria for electrocardiographic interpretation in athletes: Consensus statement. **2017**, 51, 704-731		159
1084	[Sudden cardiac death : Epidemiology, pathophysiology and risk stratification]. **2017**, 42, 123-131		2
1083	Role of the molecular autopsy in the investigation of sudden cardiac death. **2017**, 45, 17-23		7
1082	Red Bull : Red flag or red herring?. **2017**, 231, 179-180		2
1081	Cardiovascular Effects of Energy Drinks in Familial Long QT Syndrome: A Randomized Cross-Over Study. **2017**, 231, 150-154		23
1080	Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. **2017**, 69, 2134-2145		126
1079	Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome. **2017**, 137, 256-260		14
1078	Implantable cardioverter defibrillator and catheter ablation in Brugada syndrome. **2017**, 18 Suppl 1, e35-e39		2
1077	Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome. **2017**, 10, e005053		112
1076	Next Generation Sequencing Based Clinical Molecular Diagnosis of Human Genetic Disorders. **2017**,		0
1075	Usefulness of the R-Wave Sign as a Predictor for Ventricular Tachyarrhythmia in Patients With Brugada Syndrome. **2017**, 120, 428-434		9
1074	Ventricular and Supraventricular Ectopy in Subjects With Early Repolarization. **2017**, 120, 92-97		4
1073	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart Rhythm*, **2017**, 14, e55-e96	6.7	136
1072	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. **2017**, 22, e12447		35
1071	[Malignant bileaflet mitral valve prolapse syndrome in otherwise idiopathic ventricular fibrillation]. **2017**, 28, 232-235		

1070	Long-term prognosis of drug-induced Brugada syndrome. *Heart Rhythm*, **2017**, 14, 1427-1433	6.7	18
1069	Evaluation of baseline ECG in patients undergoing Oral Flecainide Challenge test for suspected Brugada Syndrome: An analysis of lead II. **2017**, 17, 102-107		2
1068	Differences in the onset mode of ventricular tachyarrhythmia between patients with J wave in anterior leads and those with J wave in inferolateral leads. *Heart Rhythm*, **2017**, 14, 553-561	6.7	5
1067	Molecular genetic diagnostics for ventricular arrhythmias and sudden cardiac death syndromes. **2017**, 42, 476-484		0
1066	A Clinical Score Model to Predict Lethal Events in Young Patients (≤19 Years) With the Brugada Syndrome. **2017**, 120, 797-802		32
1065	Application of NGS in the Diagnosis of Cardiovascular Genetic Diseases. **2017**, 243-286		
1064	Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. *Heart Rhythm*, **2017**, 14, 866-874	6.7	27
1063	Brugada syndrome: A general cardiologist's perspective. **2017**, 44, 19-27		22
1062	The value of performing invasive risk stratification in young patients with the Brugada syndrome. **2017**, 27, 1444-1445		2
1061	In search of the holy grail in the channelopathy field: Proving pathogenicity of long QT syndrome-associated variants?. *Heart Rhythm*, **2017**, 14, 1180-1181	6.7	1
1060	Long QT syndrome: Who needs a transplant?. *Heart Rhythm*, **2017**, 14, 1189-1190	6.7	
1059	Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes. **2017**, 176, 48-59		21
1058	Genotype Positive Long QT Syndrome in Patients With Coexisting Congenital Heart Disease. **2017**, 120, 256-261		3
1057	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. **2017**, 33, 977-990		4
1056	Progression of early repolarization patterns at a four year follow-up in a female flight crew population: Implications for aviation medicine. **2017**, 22,		4
1055	Family Screening for Brugada Syndrome in Asymptomatic Young Patients. Is it Better not to Know?. **2017**, 38, 1313-1314		1
1054	Genetic Polymorphisms Associated With Increased Defibrillator Shocks in Brugada Syndrome. **2017**, 6,		18
1053	LAMP2 shines a light on cardiomyopathy in an athlete. **2017**, 3, 172-176		2

1052	Genotype-phenotype dilemma in a case of sudden cardiac death with the E1053K mutation and a deletion in the SCN5A gene. **2017**, 275, 187-194	10
1051	Short QT syndrome in pediatrics. **2017**, 106, 393-400	12
1050	Value of the "Standing Test" in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome. **2017**, 70, 907-914	1
1049	Genotype-Phenotype Correlation of Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry. **2017**, 135, 2255-2270	88
1048	Prevention of Sudden Cardiac Death in Children and Young Adults. **2017**, 45, 37-42	8
1047	Systematic review of risk stratification of pediatric ventricular arrhythmia in structurally normal and abnormal hearts. **2017**, 45, 55-62	1
1046	What Is the Best Age for Diagnostic Prediction of Pediatric Long-QT Syndrome With a Borderline QT Interval?. **2017**, 10,	1
1045	Arrhythmia risk and Eblocker therapy in pregnant women with long QT syndrome. **2017**, 103, 1374-1379	25
1044	Distribution and Prognostic Significance of Fragmented QRS in Patients With Brugada Syndrome. **2017**, 10,	24
1043	Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force Recommendation. **2017**, 166, 451-452	7
1042	Acute Myocardial Infarction Masked by Brugada Syndrome: A Case Report. **2017**, 166, 449-450	
1041	Cardiac sympathetic denervation 100years later: Jonnesco would have never believed it. **2017**, 237, 25-28	17
1040	Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report. **2017**, 166, 450-451	10
1039	The Current State and Future Potential´of´Pediatric and Congenital´Electrophysiology. **2017**, 3, 195-206	2
1038	Investigation of the family of sudden cardiac death victims. **2017**, 45, 25-29	1
1037	2016 AHA/ACC Clinical Performance and Quality Measures´for Prevention of Sudden´Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. **2017**, 69, 712-744	18
1036	Variants of Brugada Syndrome and Early Repolarization Syndrome: An Expanded Concept of J-Wave Syndrome. **2017**, 40, 162-174	3
1035	Video-Assisted Thoracoscopic Left Cardiac Sympathetic Denervation in Patients with Hereditary Ventricular Arrhythmias. **2017**, 40, 232-241	9

1034	Issues and Challenges in Diagnostic Sequencing for Inherited Cardiac Conditions. **2017**, 63, 116-128	6
1033	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. **2017**, 10, e000022	6
1032	Clockwork and Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. **2017**, 3, 1318-1320	
1031	Ventricular tachycardia as the first manifestation of disease: an element with different clinical settings. **2017**, 18 Suppl 1, e77-e82	
1030	Cardiac Arrhythmias Related to Sodium Channel Dysfunction. **2018**, 246, 331-354	24
1029	Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy. **2017**, 3, 470-474	9
1028	Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. **2017**, 136, e273-e344	105
1027	Genomic Triangulation and Coverage Analysis in Whole-Exome Sequencing-Based Molecular Autopsies. **2017**, 10,	12
1026	Ventricular Arrhythmias in the Absence of Structural Heart Disease. **2017**, 205-217	
1025	Electrophysiologic Testing and Cardiac Mapping. **2017**, 75-86	
1024	Brugada Syndrome: Lessons in Risk Tolerance, Communication, and Education?. **2017**, 70, 2003-2005	
1023	Syncope in patients with inherited arrhythmias. **2017**, 33, 572-578	4
1022	[Asymptomatic Brugada syndrome: From diagnosis to treatment]. **2017**, 66, 295-298	
1021	Normal Ventricular Repolarization and QT Interval: Ionic Background, Modifiers, and Measurements. **2017**, 9, 487-513	14
1020	Differential methylation of lncRNA KCNQ1OT1 promoter polymorphism was associated with symptomatic cardiac long QT. **2017**, 9, 1049-1057	22
1019	Clinical Yield of Familial Screening After Sudden Death in Young Subjects: The French Experience. **2017**, 10,	17
1018	Efficacy of Familial Screening After Sudden Cardiac Death in Young Adults Irrespective of Postmortem Analysis: Implication of a Pharmacological Challenge as a First Step of Screening. **2017**, 10,	1
1017	Classification, Epidemiology, and Global Burden of Cardiomyopathies. **2017**, 121, 722-730	161

1016	Syncope and the risk of sudden cardiac death: Evaluation, management, and prevention. **2017**, 33, 533-544	27
1015	Read My Lips: A Positive Ajmaline Test Does Not Always Mean You´Have´Brugada Syndrome. **2017**, 3, 1409-1411	5
1014	Acute arrhythmias: general principles of management. **2017**, 258-262	
1013	Beyond the Electrocardiogram: Mutations in Cardiac Ion Channel Genes Underlie Nonarrhythmic Phenotypes. **2017**, 11, 1179546817698134	4
1012	Channelopathies: Clinical Presentation and Genetics. **2017**, 37-47	
1011	Inaccurate diagnosis of Brugada syndrome in a healthy woman based on SCN5A mutation classification. **2017**, 3, 450-454	4
1010	Sudden infant death syndrome and inherited cardiac conditions. **2017**, 14, 715-726	22
1009	Differential calcium sensitivity in Na 1.5 mixed syndrome mutants. **2017**, 595, 6165-6186	10
1008	Valor del «test de bipedestaci□» en el diagn□stico y la evaluaci□ de la respuesta al tratamiento con bloqueadores beta en el s□ndrome de QT largo. **2017**, 70, 907-914	1
1007	Contemporary Outcomes in Patients With´Long QT Syndrome. **2017**, 70, 453-462	48
1006	Postmortem genetic analysis of sudden unexpected death in infancy: neonatal genetic screening may enable the prevention of sudden infant death. **2017**, 62, 989-995	14
1005	QTc Interval in Adolescents and Young Athletes: Influence of Correction Formulas. **2017**, 38, 729-734	5
1004	Double jeopardy: long QT3 and Brugada syndromes. **2017**, 5, 1315-1319	6
1003	A case of long QT syndrome: challenges on a bumpy road. **2017**, 5, 954-960	2
1002	D242N, a K7.1 LQTS mutation uncovers a key residue for I voltage dependence. **2017**, 110, 61-69	8
1001	Impact of electrocardiogram screening during drug challenge test for the prediction of T-wave oversensing by a subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. **2017**, 32, 1277-1283	9
1000	Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. **2017**, 32, 78-85	13
999	Value of the sodium-channel blocker challenge in Brugada syndrome. **2017**, 245, 178-180	12

998	Investigating the Genetic Causes of Sudden Unexpected Death in Children Through Targeted Next-Generation Sequencing Analysis. **2017**, 10,		15
997	Genetic Testing in Inherited Heart Diseases: Practical Considerations for Clinicians. **2017**, 19, 88		8
996	Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. **2017**, 28, 1454-1459		14
995	Induced Brugada syndrome: Possible sources of arrhythmogenesis. **2017**, 36, 945-956		5
994	Brugada syndrome revealed by intestinal shigellosis in a patient from Benin at the University Hospital of Saint-Etienne. **2017**, 110, 250-253		2
993	Sudden Cardiac Death in Children and Adolescents. **2017**, 9, 569-579		7
992	Prediction and Prevention of Sudden Cardiac Death. **2017**, 9, 631-638		21
991	Channelopathies as Causes of Sudden Cardiac Death. **2017**, 9, 537-549		19
990	Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome. **2017**, 8, 1696		46
989	Delayed diagnosis of Brugada syndrome in a patient with aborted sudden cardiac death and initial negative flecainide challenge. **2017**, 5, 2022-2024		8
988	How often is patent foramen ovale an innocent bystander?. **2017**, 5, 1992-1994		2
987	Criteria for short QT interval based on a new QT-heart rate adjustment formula. **2017**, 33, 525-527		3
986	Novel trigenic CACNA1C/DES/MYPN mutations in a family of hypertrophic cardiomyopathy with early repolarization and short QT syndrome. **2017**, 15, 78		18
985	Shortening of the Short Refractory Periods in Short QT Syndrome. **2017**, 6,		5
984	Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity. *Heart Rhythm*, **2017**, 14, 1442-1448	6.7	29
983	Motor Vehicle Collision Secondary to Ventricular Dysrhythmia:´A Case Report of Brugada Syndrome. **2017**, 52, 227-230		
982	Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model. *Heart Rhythm*, **2017**, 14, 448-454	6.7	17
981	Molecular Pathophysiology of Congenital Long QT Syndrome. **2017**, 97, 89-134		92

980	Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. **2017**, 227, 668-673		20
979	Prominent QTc prolongation in a patient with a rare variant in the cardiac ryanodine receptor gene. **2017**, 32, 229-233		7
978	Low-Dose Quinidine Effectively Reduced Shocks in Brugada Syndrome Patients with an Implantable Cardioverter Defibrillator: A Chinese Case Series Report. **2017**, 22,		8
977	Is Symptomatic Long QT Syndrome Associated with Depression in Women and Men?. **2017**, 26, 491-500		5
976	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. *Heart Rhythm*, **2017**, 14, e41-e44	6.7	60
975	Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. **2017**, 19, 521-528		20
974	Sudden death and cardiac arrest without phenotype: the utility of genetic testing. **2017**, 27, 207-213		10
973	ST segment depression in the inferior leads in Brugada Pattern: It's time to look for it. **2017**, 59, e210-e212		1
972	A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. **2017**, 50, 227-233		26
971	Medico-legal perspectives on sudden cardiac death in young athletes. **2017**, 131, 393-409		15
970	Induced Brugada syndrome: Possible sources of arrhythmogenesis. **2017**, 36, 945-956		3
969	Routinely collected health data to study inherited heart disease: a systematic review (2000-2016). **2017**, 4, e000686		2
968	Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. **2017**, 2, 759-766		80
967	Literatur. **2017**,		
966	Les canalopathies : quels progr□ dans la pr√vention de la mort subite ?. **2017**, 201, 809-819		
965	Recent advances in the management of ventricular tachyarrhythmias. **2017**, 6, 1027		4
964	How to measure a QT interval. **2017**, 207, 107-110		6
963	Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. **2017**, 6,		63

962	Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome. **2017**, 58, 720-723		10
961	Mid-Term Follow-up of School-Aged Children With Borderline Long QT Interval. **2017**, 81, 726-732		1
960	Drug-induced Brugada-type Electrocardiogram: A Cause of Sudden Death in Patients with Schizophrenia?. **2017**, 56, 2969-2970		2
959	A mutation in the CACNA1C gene leads to early repolarization syndrome with incomplete penetrance: A Chinese family study. **2017**, 12, e0177532		12
958	A Common Variant in SCN5A and the Risk of Ventricular Fibrillation Caused by First ST-Segment Elevation Myocardial Infarction. **2017**, 12, e0170193		11
957	PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function K2.1 channels, but increases channel protein expression. **2017**, 24, 44		10
956	Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies. **2017**, 24, 56		17
955	Implantable Cardioverter-Defibrillators in Inherited Arrhythmia Syndromes. **2017**, 566-578		
954	QT Prolongation and Malignant Arrhythmia: How Serious a Problem?. **2017**, 12, 112-120		15
953	A Carbamazepine-induced Brugada-type Electrocardiographic Pattern in a Patient with Schizophrenia. **2017**, 56, 3047-3050		3
952	The role of sympathectomy in long QT syndrome. **2017**, 9, 3394-3397		5
951	Hypoxic Challenge Testing (Fitness to Fly) in children with complex congenital heart disease. **2018**, 104, 1333-1338		10
950	A case report of Brugada-like ST-segment elevation probably due to coronary vasospasm. **2018**, 97, e9900		0
949	Cardiac Channelopathies: Recognition, Treatment, Management. **2018**, 29, 43-57		2
948	Diagnosis and management of short QT syndrome. *Heart Rhythm*, **2018**, 15, 1261-1267	6.7	27
947	Maximum QTc on Holter electrocardiography in children. **2018**, 60, 507-512		2
946	Early repolarization is involved in ventricular fibrillation in patients with variant angina. **2018**, 41, 734-740		2
945	Hot topics in Brugada syndrome. *Heart Rhythm*, **2018**, 15, 1402-1403	6.7	1

944	Multiple genetic variations in sodium channel subunits in a case of sudden infant death syndrome. **2018**, 41, 620-626		2
943	Genetic risk stratification in cardiac arrhythmias. **2018**, 33, 298-303		4
942	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. **2018**, 71, 1663-1671		76
941	Programmed Ventricular Stimulation and Brugada Syndrome: New Insights, Old Controversies. **2018**, 71, 1647-1649		1
940	Phenotypic Landscape and Risk Management in Long QT Syndrome: Nudging Forward. **2018**, 71, 1672-1675		2
939	Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes. **2018**, 37, 435-446		10
938	Arrhythmia Identification: Stabilization and Treatment. **2018**, 131-160		
937	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2018**, 15, 1394-1401	6.7	49
936	Yield of the Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. **2018**, 11, e001424		20
935	A hERG mutation E1039X produced a synergistic lesion on I together with KCNQ1-R174C mutation in a LQTS family with three compound mutations. **2018**, 8, 3129		2
934	Significance of T-wave inversion triggered by spontaneous atrial premature beats in patients with long QT syndrome. *Heart Rhythm*, **2018**, 15, 860-869	6.7	5
933	Athletes with channelopathy may be eligible to play. **2018**, 26, 146-153		3
932	Inherited Conduction Disease and Atrial Fibrillation. **2018**, 481-522		
931	Ablation of Catecholaminergic Polymorphic Ventricular Tachycardia. **2018**, 365-370		
930	Unsafe Drug Use and Arrhythmic Events in Brugada Patients with ICD: Results of a Long-Term Follow-Up. **2018**, 32, 23-28		1
929	Sudden cardiac arrest during marathon training in a young adult with short QT syndrome. **2018**, 18, 101-103		3
928	An unusual presentation of asymptomatic Type 2 Brugada pattern. **2018**, 8, 40-42		
927	Editorial commentary: Brugada syndrome or not? That is the question. **2018**, 28, 293-294		1

926	Controversies in Brugada syndrome. **2018**, 28, 284-292		5
925	The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. **2018**, 9, 257-262		5
924	Concealed abnormal atrial phenotype in patients with Brugada syndrome and no history of atrial fibrillation. **2018**, 253, 66-70		6
923	Implantable Cardioverter-Defibrillators in Children and Adolescents With Brugada Syndrome. **2018**, 71, 148-157		29
922	Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. **2018**, 4, 569-579		91
921	Genotype-phenotype relationship and risk stratification in loss-of-function SCN5A mutation carriers. **2018**, 23, e12548		4
920	Beyond the length and look of repolarization: Defining the non-QTc electrocardiographic profiles of patients with congenital long QT syndrome. *Heart Rhythm*, **2018**, 15, 1413-1419	6.7	9
919	Shanghai Score System for Diagnosis of Brugada Syndrome: Validation of the Score System and System and Reclassification of the Patients. **2018**, 4, 724-730		21
918	Perioperative management of patients with congenital or acquired disorders of the QT interval. **2018**, 120, 629-644		16
917	Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results. **2018**, 107, 670-678		5
916	A novel three base-pair deletion in domain two of the cardiac sodium channel causes Brugada syndrome. **2018**, 51, 667-673		0
915	Cardiac channelopathies: The role of sodium channel mutations. **2018**, 37, 179-199		2
914	ST elevation: Differential diagnosis and caveats. A comprehensive review to help distinguish ST elevation myocardial infarction from nonischemic etiologies of ST elevation. **2018**, 18, 1-10		20
913	Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. **2018**, 24, 281-302		160
912	The importance of a comprehensive evaluation of survivors of cardiac arrest. **2018**, 39, 1988-1991		2
911	Cardiac channelopathies: The role of sodium channel mutations. **2018**, 37, 179-199		6
910	International recommendations for electrocardiographic interpretation in athletes. **2018**, 39, 1466-1480		137
909	Multiple targets for flecainide action: implications for cardiac arrhythmogenesis. **2018**, 175, 1260-1278		30

908	Distinguishing pathogenic mutations from background genetic noise in cardiology: The use of large genome databases for genetic interpretation. **2018**, 93, 459-466		16
907	High thoracic left sympathectomy for recalcitrant ventricular tachyarrhythmias and long QT syndrome. **2018**, 34, 103-108		1
906	Comparisons of clinical impacts on individuals with Brugada electrocardiographic patterns defined by ISHNE criteria or EHRA/HRS/APHRS criteria: a nationwide community-based study. **2018**, 50, 7-15		4
905	Transient left septal and anterior fascicular block associated with type 1 electrocardiographic Brugada pattern. **2018**, 51, 145-149		4
904	Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor. **2018**, 39, 1456-1458		2
903	The Genetic Counselor in the Pediatric Arrhythmia Clinic: Review and Assessment of Services. **2018**, 27, 558-564		8
902	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* **2018**, 15, e190-e252	6.7	264
901	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart*	6.7	151
900	Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 72, 1653-1676		27
899	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart		180
898	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 138, e210-e271		173
897	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**,		307
896	Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 138, e392-e414		17
895	Brugada phenocopy associated with diabetic ketoacidosis in two pediatric patients. **2018**, 51, 323-326		7
894	Impact of QTc formulae in the prevalence of short corrected QT interval and impact on probability and diagnosis of short QT syndrome. **2018**, 104, 502-508		16
893	Diagnosis and clinical management of long-QT syndrome. **2018**, 33, 31-41		22
892	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. **2018**, 250, 139-145		22
891	Identification of electrocardiographic risk markers for the initial and recurrent episodes of ventricular fibrillation in patients with Brugada syndrome. **2018**, 29, 107-114		22

890	Genetic, Ionic, and Cellular Mechanisms Underlying the J Wave Syndromes. **2018**, 483-493		1
889	Inheritable Phenotypes Associated With Altered Intracellular Calcium Regulation. **2018**, 504-512		
888	Pharmacological Bases of Antiarrhythmic Therapy. **2018**, 513-524		2
887	Exercise-Induced Arrhythmias. **2018**, 615-622		
886	Ventricular Tachycardias in Catecholaminergic Cardiomyopathy (Catecholaminergic Polymorphic Ventricular Tachycardia). **2018**, 850-857		
885	Long and Short QT Syndromes. **2018**, 893-904		2
884	Idiopathic Ventricular Fibrillation. **2018**, 925-931		
883	Sex Differences in Arrhythmias. **2018**, 1011-1019		0
882	Systematic review for the 2017´AHA/ACC/HRS guideline for management of patients with ventricular´arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*, **2018**, 15, e253-e274	6.7	10
881	Cardiac arrest and Brugada syndrome: Is drug-induced type 1 ECG pattern always a marker of low risk?. **2018**, 254, 142-145		9
880	Prevalence of spontaneous Brugada ECG pattern recorded at standard intercostal leads: A meta-analysis. **2018**, 254, 151-156		13
879	Ventricular Arrhythmias. **2018**, 197-225		
878	Channelopathies. **2018**, 283-302		
877	Arrhythmetics and the Magic Numbers in Cardiology. **2018**, 31-35		
876	Communication of genetic information to families with inherited rhythm disorders. *Heart Rhythm*, **2018**, 15, 780-786	6.7	21
875	General and regional anaesthesia in Brugada Syndrome A case report. **2018**, 19, 16-18		2
874	Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. **2018**, 19, 1-11		33
873	Theophylline: The forgotten antiarrhythmic drug how for malignant early repolarization. **2018**, 41, 441-443		1

872	Pharmacological Therapy in Brugada Syndrome. **2018**, 7, 135-142	21
871	Catecholaminergic Polymorphic Ventricular Tachycardia. **2018**, 542-552	
870	Predictors of Eblocker adherence in cardiac inherited disease. **2018**, 5, e000877	4
869	Genetic Disease Modifying Future Career: A Case Report of Long QT Syndrome. **2018**, 08,	
868	OBSOLETE: Ion Channelopathy Genetics. **2018**,	
867	OBSOLETE: Catecholaminergic Polymorphic Ventricular Tachycardia. **2018**,	
866	OBSOLETE: Clinical Management of Inherited Arrhythmias. **2018**,	
865	Concomitant SK current activation and sodium current inhibition cause J wave syndrome. **2018**, 3,	11
864	Clinical Management of Inherited Arrhythmias. **2018**, 620-629	
863	Impact of genetic studies on comprehension and treatment of congenital heart disease. **2018**, 51, 31-36	
862	An African loss-of-function CACNA1C variant p.T1787M associated with a risk of ventricular fibrillation. **2018**, 8, 14619	5
861	Interpreting the Athlete's ECG: Current State and Future Perspectives. **2018**, 20, 104	11
860	Electroanatomic and Pathologic Right Ventricular Outflow Tract Abnormalities in Patients With Brugada Syndrome. **2018**, 72, 2747-2757	38
859	Management of Brugada Syndrome in the Developing Countries. **2018**, 12, 1	
858	Advanced techniques in ECG. **2018**, 13, 440-445	
857	Recent Advances in Short QT Syndrome. **2018**, 5, 149	36
856	Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry. **2018**, 13, e0205925	22
855	Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies. **2018**, 7, e010595	48

854	Is Careful Assessment of Rare Variants in the Gene Piercing the Guidelines' Strong Armor?. **2018**, 11, e002072	
853	Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation. **2018**, 13, e0207100	12
852	Early Repolarization Syndrome: Diagnostic and Therapeutic Approach. **2018**, 5, 169	12
851	Electrophysiology Approaches for Ventricular Tachycardia. **2018**, 211-220	0
850	Determination and Interpretation of the QT Interval. **2018**, 138, 2345-2358	53
849	Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. **2018**, 138, e653-e711	184
848	Brugada Syndrome Associated With Adolescent Loperamide Abuse. **2018**, 142,	8
847	Cochlear implantation in children with congenital long QT syndrome: Introduction of an evidence-based pathway of care. **2018**, 19, 350-354	3
846	Key Role of the Membrane Trafficking of Nav1.5 Channel Protein in Antidepressant-Induced Brugada Syndrome. **2018**, 9, 1230	5
845	Channelopathies in Heart Disease. **2018**,	
844	Gender Differences in Prognosis and Risk Stratification of Brugada Syndrome: A Pooled Analysis of 4,140 Patients From 24 Clinical Trials. **2018**, 9, 1127	12
843	Variants: Association With Cardiac Disorders. **2018**, 9, 1372	47
842	Video-Assisted Thoracoscopic Left Cardiac Sympathetic Denervation in Chinese Patients with Long QT Syndrome. **2018**, 59, 1346-1351	7
841	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. **2018**, 34, 1371-1392	144
840	Heart Genomics. **2018**,	
839	Progress of Genomics in Cardiac Conduction and Rhythm Disorders. **2018**, 241-280	
838	A Lucky Accident: Brugada Syndrome Associated with Out-of-Hospital Cardiac Arrest. **2018**, 2018, 1465867	1
837	Sex-Dependent Phenotypic Variability of an SCN5A Mutation: Brugada Syndrome and Sick Sinus Syndrome. **2018**, 7, e009387	11

836	Sudden Cardiac Death and Arrhythmias. **2018**, 7, 111-117	59
835	Higher Dispersion Measures of Conduction and Repolarization in Type 1 Compared to Non-type 1 Brugada Syndrome Patients: An Electrocardiographic Study From a Single Center. **2018**, 5, 132	11
834	Mapping and Ablation of Idiopathic Ventricular Fibrillation. **2018**, 5, 123	18
833	New risk stratification on SCN5A mutation in Brugada syndrome. **2018**, 271, 123	1
832	Idiopathic Ventricular Fibrillation and Early Repolarization. **2018**, 257-275	
831	Long and Short QT Syndromes. **2018**, 147-185	
830	Supraventricular and ventricular arrhythmias: interventional management. **2018**, 46, 640-645	
829	Development of monomorphic ventricular tachycardia in a patient with fever-induced Brugada syndrome. **2018**, 34, 465-468	
828	Cardiac Screening of Young Athletes: a Practical Approach to Sudden Cardiac Death Prevention. **2018**, 20, 85	7
827	The role of mexiletine in the management of long QT syndrome. **2018**, 51, 1061-1065	18
826	High prevalence of ventricular repolarization abnormalities in people carrying TGFBR2 mutations. **2018**, 8, 13019	4
825	Diagnostic Yield of Genetic Testing in Young Athletes With T-Wave Inversion. **2018**, 138, 1184-1194	31
824	[Syncopes and channelopathies]. **2018**, 29, 171-177	
823	Syncope: Electrocardiographic and Clinical Correlation. **2018**, 10, 371-386	2
822	Another step towards a mechanism-based, subtype-specific therapy in long QT syndrome. **2018**, 263, 67-68	
821	Right coronary anomaly in a patient with myocarditis and cardiac arrest: a case report. **2018**, 2, yty044	
820	Cardiac events occurred commonly among apparently healthy Filipinos with the Brugada ECG pattern in the LIFECARE cohort. **2018**, 10, e010969	1
819	J-Wave Syndromes: Electrocardiographic and Clinical Aspects. **2018**, 10, 355-369	8

818	Role of genetic heart disease in sentinel sudden cardiac arrest survivors across the age spectrum. **2018**, 270, 214-220		17
817	Visual Diagnosis: Syncopal Episode in a 14-year-old Adolescent Boy. **2018**, 39, e27-e30		
816	Cardiac Emergencies in Children. **2018**,		
815	Arrhythmias in Right Heart Disease. **2018**, 417-428		
814	For neonatal ECG screening there is no reason to relinquish old Bazett's correction. **2018**, 39, 2888-2895		19
813	Lack of genotype-phenotype correlation in Brugada Syndrome and Sudden Arrhythmic Death Syndrome families with reported pathogenic SCN1B variants. *Heart Rhythm*, **2018**, 15, 1051-1057	6.7	10
812	Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes. **2018**, 37, 435-446		4
811	CRISPRed Cardiomyocytes to Decrypt Variants of Uncertain Significance. **2018**, 72, 76-78		
810	Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. **2018**, 3, 775-776		1
809	Relations between right ventricular morphology and clinical, electrical and genetic parameters in Brugada Syndrome. **2018**, 13, e0195594		16
808	Anaesthesia for patients with hereditary arrhythmias; part 2: congenital long QT syndrome and arrhythmogenic right ventricular cardiomyopathy. **2018**, 18, 246-253		0
807	Republication de´: Syndrome de Brugada asymptomatique´: diagnostic, pronostic, nouvelles strat□gies th□apeutiques. **2018**, 30, 7-10		
806	The Athlete□ Electrocardiogram. **2018**, 147-178		
805	Sports and Exercise Participation for Individuals with Implantable Cardioverter-Defibrillators or Pacemakers. **2018**, 323-344		
804	The Value of the Sodium Channel Blocker Test in Brugada Syndrome and Brugada Phenocopy. **2018**, 21-31		
803	The ECG of the Athlete and the Differential Diagnosis With the Brugada ECG Pattern. **2018**, 93-98		
802	Wearable cardioverter defibrillators for patients with long QT syndrome. **2018**, 268, 132-136		8
801	Brugada syndrome and undifferentiated syncope: use of an implantable loop recorder to document causation. **2018**, 209, 113-114		5

800	Identification of an I-dependent and I-mediated proarrhythmic mechanism in cardiomyocytes derived from pluripotent stem cells of a Brugada syndrome patient. **2018**, 8, 11246		20
799	SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. **2018**, 39, 2879-2887		18
798	Genotype and clinical characteristics of congenital long QT syndrome in Thailand. **2018**, 18, 165-171		3
797	Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. *Heart Rhythm*, **2018**, 15, 1791-1799	6.7	42
796	Familiäre Arrhythmieerkrankungen mit strukturell normalen Herzen. **2018**, 7, 190-196		
795	Ion Channel Disorders and Sudden Cardiac Death. **2018**, 19,		40
794	Life-long tailoring of diagnosis and management of patients with idiopathic ventricular fibrillation-future perspectives in research. **2018**, 26, 367-374		
793	Functional Invalidation of Putative Sudden Infant Death Syndrome-Associated Variants in the -Encoded Kv11.1 Channel. **2018**, 11, e005859		3
792	Guidelines for Heart Disease Screening in Schools (JCS 2016/JSPCCS 2016) - Digest Version. **2018**, 82, 2385-2444		10
791	Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies. **2018**, 96, 993-1024		3
790	Electrocardiogram screening of deaf children for long QT syndrome: An Egyptian experience. **2018**, 41, 1414-1419		0
789	All Along the Watchtower: a Case of Long QT Syndrome Misdiagnosis Secondary to Genetic Testing Misinterpretation. **2018**, 27, 1515-1522		3
788	Arrhythmias precede cardiomyopathy and remodeling of Ca handling proteins in a novel model of long QT syndrome. **2018**, 123, 13-25		2
787	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**,		411
786	Retrospective Genetic Analysis of 200 Cases of Sudden Infant Death Syndrome and Its Relationship with Long QT Syndrome in Korea. **2018**, 33, e200		4
785	A Shocking Turn of Events. **2018**, 378, 2225-2230		2
784	J wave syndromes as a cause of malignant cardiac arrhythmias. **2018**, 41, 684-699		9
783	Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. **2018**, 38, 813-821		22

782	A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. **2018**, 266, 89-94	30
781	The Shanghai Score System in Brugada Syndrome: Using it Beyond a Diagnostic Score. **2018**, 4, 731-732	1
780	Importance of Variant Interpretation in Whole-Exome Molecular Autopsy: Population-Based Case Series. **2018**, 137, 2705-2715	23
779	Atrial fibrillation in young patients. **2018**, 16, 489-500	12
778	Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. **2019**, 44, 92-106	32
777	Essentials of Cardiology. **2019**, 355-392.e6	2
776	A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. **2019**, 5, 74-77	2
775	SCN5A mutation status increases the risk of major arrhythmic events in Asian populations with Brugada syndrome: systematic review and meta-analysis. **2019**, 24, e12589	6
774	Brugada Syndrome: Progress in Genetics, Risk Stratification and Management. **2019**, 8, 19-27	6
773	Speckle tracking echocardiography data in Brugada syndrome patients. **2019**, 25, 104330	
772	Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders. **2019**, 140, 595-610	56
771	Diagnostic evaluation and arrhythmia mechanisms in survivors of unexplained cardiac arrest. **2019**, 42, 1320-1330	2
770	Inherited Cardiac Arrhythmias and Channelopathies. **2019**, 103, 809-820	11
769	Cardiac Evaluation of Children With a Family History of Sudden Death. **2019**, 74, 759-770	3
768	Findings of Uncertain Significance and a Family History of Sudden Death: Worth the FUSs?. **2019**, 74, 771-773	
767	Phenotype-Based High-Throughput Classification of Long QT Syndrome Subtypes Using Human Induced Pluripotent Stem Cells. **2019**, 13, 394-404	19
766	Evaluation After Sudden Death in the Young: A Global Approach. **2019**, 12, e007453	10
765	Brugada syndrome: updated perspectives. **2019**, Volume 10, 19-32	2

764	Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants. **2019**, 8,		17
763	Should we do 'whatever it takes' or 'whatever is best' to prevent cardiac arrest in high-risk patients?. **2019**, 40, 2962-2963		1
762	Brugada pattern: a comprehensive review on the demographic and clinical spectrum. **2019**, 12,		1
761	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. **2019**, 21, 1143-1144		114
760	Idiopathic ventricular fibrillation - Long term prognosis in relation to clinical findings and ECG patterns in a Swedish cohort. **2019**, 56, 46-51		2
759	Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia. **2019**, 30, 1923-1929		6
758	Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. **2019**, 30, 1939-1948		10
757	Could This Cardiac Arrest Have Been Prevented?. **2019**, 221-228		
756	Cardiac Arrhythmias. **2019**, 172-177		
755	Arrhythmias due to Inherited and Acquired Abnormalities of Ventricular Repolarization. **2019**, 11, 345-362		4
754	Monitoring risk for sudden cardiac death: is there a role for EKG patches?. **2019**, 11, 117-123		4
753	Biomarkers in Forensic Diagnosis of Sudden Cardiac Death (SCD). **2019**, 1, 1248-1255		
752	Spectral Analysis of the QT Interval Increases the Prediction Accuracy of Clinical Variables in Brugada Syndrome. **2019**, 8,		3
751	A 45-Year-Old Man with Chest Pain After an Automobile Accident. **2019**, 9-12		
750	CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia. **2019**, 7, e949		6
749	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
748	Cardiac Arrhythmias and Pregnancy. **2019**, 220-251		
747	Canadian Cardiovascular Society Cardiovascular Screening of Competitive Athletes: The Utility of the Screening Electrocardiogram to Predict Sudden Cardiac Death. **2019**, 35, 1557-1566		9

746	Rare Genetic Variants Associated With Sudden Cardiac Death in Adults. **2019**, 74, 2623-2634	17
745	. **2019**,	
744	Detection of concealed structural heart disease by imaging in patients with apparently idiopathic premature ventricular complexes: A review of current literature. **2019**, 42, 1162-1169	5
743	Update on long QT syndrome. **2019**, 30, 3068-3078	21
742	3,4-Dimethoxychalcone induces autophagy through activation of the transcription factors TFE3 and TFEB. **2019**, 11, e10469	33
741	Impact of RNA testing on cardiac variant interpretation and patient management. **2019**, 5, 402-406	
740	Neuromodulation for Ventricular Tachycardia and Atrial Fibrillation: A Clinical Scenario-Based Review. **2019**, 5, 881-896	15
739	Sudden Cardiac Death in the Young. **2019**, 327-341	
738	Impact of Ethnicity on the Prevalence of Early Repolarization Pattern in Children: Comparison Between Caucasian and African Populations. **2019**, 40, 1553-1558	3
737	Sudden Cardiac Death: Who Is at Risk?. **2019**, 103, 913-930	16
736	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. **2019**, 125, 653-658	28
735	Predicting Arrhythmia Risk in Dilated´Cardiomyopathy Using Genetic´Mutation´Status. **2019**, 74, 1491-1493	2
734	Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors. **2019**, 40, 1679-1687	12
733	Syncope Due to Ventricular Arrhythmia Triggered by Electronic Gaming. **2019**, 381, 1180-1181	6
732	Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts. **2019**, 20, 2101-2114	4
731	Sudden infant death as the most severe phenotype caused by genetic modulation in a family with atrial fibrillation. **2019**, 43, 102159	0
730	The Effect of Left Cardiac Sympathetic Denervation on Exercise in Patients With Long QT Syndrome. **2019**, 5, 1084-1090	0
729	Out-of-Hospital Cardiac Arrest Due to a Concealed Diagnosis. **2019**, 1, 339-342	

728	Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells. **2019**, 19, 313-333		4
727	Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. **2019**, 139, 2304-2314		25
726	Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. **2019**, 139, 1786-1797		70
725	Impact of Ancestral Differences and Reassessment of the Classification of Previously Reported Pathogenic Variants in Patients With Brugada Syndrome in the Genomic Era: A SADS-TW BrS Registry. **2018**, 9, 680		6
724	Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. **2019**, 123, 1156-1162		5
723	Clinical Characteristics and Electrophysiological Mechanisms Underlying Brugada ECG in Patients With Severe Hyperkalemia. **2019**, 8, e010115		12
722	Role of the Purkinje system in heritable arrhythmias. *Heart Rhythm*, **2019**, 16, 1121-1126	6.7	13
721	Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. **2019**, 12, e000054		28
720	Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model. **2019**, 38, 101483		4
719	Markers of ventricular repolarization as an additional non-invasive electrocardiography parameters for predicting ventricular tachycardia/fibrillation in patients with Brugada Syndrome - A systematic review and meta-analysis. **2019**, 19, 205-210		1
718	Successful radiofrequency catheter ablation of a premature ventricular contraction triggering ventricular fibrillation in a patient with short QT syndrome. **2019**, 5, 262-265		2
717	Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). **2019**, 62, 227-234		23
716	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. **2019**, 40, 2953-2961		53
715	Suspicion and Persistence: A Case of Pediatric Brugada Syndrome. **2019**, 144,		1
714	Risk stratification beyond electrocardiographic manifestation in Brugada syndrome: The important parameter of PR interval. **2019**, 35, 591-592		
713	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
712	NGS-Based genetic testing for heritable cardiovascular diseases. Specific requirements for obtaining informed consent. **2019**, 45, 70-78		
711	Long-Term Follow-Up of Idiopathic Ventricular Fibrillation in a Pediatric Population: Clinical Characteristics, Management, and Complications. **2019**, 8, e011172		10

710	Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. **2019**, 40, 3110-3117	16
709	Electrocardiographic evidence of abnormal atrial phenotype in Brugada syndrome. **2019**, 55, 102-106	3
708	Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. **2019**, 12, e007280	38
707	Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance. **2019**, 12, e002510	19
706	Patient-independent human induced pluripotent stem cell model: A new tool for rapid determination of genetic variant pathogenicity in long QT syndrome. *Heart Rhythm*, **2019**, 16, 1686-1695 6.7	18
705	Informing relatives at risk of inherited cardiac conditions: experiences and attitudes of healthcare professionals and counselees. **2019**, 27, 1341-1350	8
704	Minimal inflammatory foci of unknown etiology may be a tentative sign of early stage inherited cardiomyopathy. **2019**, 32, 1281-1290	8
703	Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2. **2019**, 37, 101450	4
702	Quinidine-A legacy within the modern era of antiarrhythmic therapy. **2019**, 144, 257-263	10
701	Brugada Syndrome Caused by Autonomic Dysfunction in Multiple Sclerosis. **2019**, 2019, 3937248	1
700	Acute Management of Ventricular Arrhythmia in Patients With Suspected Inherited Heart Rhythm Disorders. **2019**, 5, 267-283	7
699	Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease. **2019**, 123, 2031-2038	7
698	Appropriate use of genetics in a young patient with atrioventricular block and family history of sudden cardiac death. **2019**, 5, 169-172	3
697	Meta-Analysis of Risk Stratification of SCN5A With Brugada Syndrome: Is SCN5A Always a Marker of Low Risk?. **2019**, 10, 103	9
696	Recent understanding of clinical sequencing and gene-based risk stratification in inherited primary arrhythmia syndrome. **2019**, 73, 335-342	16
695	A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. **2019**, 42, 1146-1154	11
694	Biventricular myocardial strain analysis using cardiac magnetic resonance feature tracking (CMR-FT) in patients with distinct types of right ventricular diseases comparing arrhythmogenic right ventricular cardiomyopathy (ARVC), right ventricular outflow-tract tachycardia (RVOT-VT), and Brugada syndrome (BrS). **2019**, 108, 1147-1162	21
693	Managing uncertainty in inherited cardiac pathologies-an international multidisciplinary survey. **2019**, 27, 1178-1185	3

692	Diagnostic reproducibility of epinephrine drug challenge interpretation in suspected long QT syndrome. **2019**, 30, 896-901		6
691	A novel prediction model for risk stratification in patients with a type 1 Brugada ECG pattern. **2019**, 55, 65-71		6
690	The Molecular Basis of Long QT Type 2 (LQT2)-related Arrhythmias. **2019**, 422-430		
689	The Impact of Embryology and Anatomy on Cardiac Electrophysiology. **2019**, 37-45		
688	Mapping and Ablation of Idiopathic Ventricular Fibrillation. **2019**, 922-933		
687	A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia family. **2019**, 62, 103631		14
686	Precision Versus Traditional Medicine-Clinical Questions Trigger Progress in Basic Science. **2019**, 124, 459-461		4
685	A Homozygous Mutation in a Japanese Patient with Catecholaminergic Polymorphic Ventricular Tachycardia. **2019**, 2019, 9056596		4
684	Pooled Analysis of Risk Stratification of Spontaneous Type 1 Brugada ECG: Focus on the Influence of Gender and EPS. **2018**, 9, 1951		8
683	Epinephrine Administered for Anaphylaxis Unmasking a Type 1 Brugada Pattern on Electrocardiogram. **2019**, 56, 444-447		1
682	Radiofrequency catheter ablation for drug-refractory atrial tachyarrhythmias in a patient with catecholaminergic polymorphic ventricular tachycardia: A case report. **2019**, 19, 36-39		1
681	Effect of beta-blockade on quantitative microvolt T-wave alternans in 24-hour continuous 12-lead ECG recordings in patients with long QT syndrome. **2019**, 24, e12640		3
680	Brugada Syndrome: anesthetic considerations and management algorithm. **2019**, 85, 173-188		5
679	Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. *Heart Rhythm*, **2019**, 16, 1232-1239	6.7	15
678	Cases in Precision Medicine: Genetic Assessment After a Sudden Cardiac Death in the Family. **2019**, 170, 710-716		0
677	Ionenkanalerkrankungen. **2019**, 13, 371-390		
676	Sport Participation in Patients with Implantable Cardioverter-Defibrillators. **2019**, 21, 66		2
675	A Review of the Emergence and Expansion of Cardiovascular Genetic Counseling. **2019**, 13, 1		

674	The challenge of implantable cardioverter-defibrillator programming and shock interpretation in treatment-refractory catecholaminergic polymorphic ventricular tachycardia. **2019**, 20, 569-571		1
673	Gender difference in Brugada syndrome: Mirror images of long QT syndrome?. *Heart Rhythm*, **2019**, 16, 268-269	6.7	
672	Systematic re-evaluation of SCN5A variants associated with Brugada syndrome. **2019**, 30, 118-127		24
671	Clinical presentation and follow-up of women affected by Brugada syndrome. *Heart Rhythm*, **2019**, 16, 260-267	6.7	17
670	Arrhythmias and Pacing. **2019**, 326-350.e3		0
669	Prevalence of spontaneous type I ECG pattern, syncope, and other risk markers in sudden cardiac arrest survivors with Brugada syndrome. **2019**, 42, 257-264		8
668	An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. **2019**, 28, 366-369		7
667	2018 ACC/AHA/HRS guideline on the´evaluation and management of´patients with bradycardia and cardiac´conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*,	6.7	30
666	2018 ACC/AHA/HRS Guideline on the´Evaluation and Management of´Patients With Bradycardia and Cardiac´Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2019**, 74, e51-e156		136
665	Plakophilin-2 Truncation Variants in Patients Clinically Diagnosed With Catecholaminergic Polymorphic Ventricular Tachycardia and Decedents With Exercise-Associated Autopsy Negative Sudden Unexplained Death in´the Young. **2019**, 5, 120-127		24
664	2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2019**, 140, e382-e482		130
663	Update on prevention and treatment of sudden cardiac arrest. **2019**, 29, 394-400		8
662	Early Repolarization: When Is It a Normal Pattern?. **2019**, 111-117		
661	Atrioventricular Conduction Abnormalities. **2019**, 255-285		
660	Ventricular Arrhythmias in Inherited Channelopathies. **2019**, 976-1041		1
659	Preprodynorphin gene mutation causes progressive cardiac conduction disease: A whole-exome analysis of a pedigree. **2019**, 219, 74-81		1
658	Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. **2019**, 5, 387-394		11
657	Clinical and Electrocardiographic Differences in Brugada Syndrome With Spontaneous or Drug-Induced Type 1 Electrocardiogram. **2019**, 83, 532-539		5

656	Abnormally high risk of stroke in Brugada syndrome. **2019**, 20, 59-65		7
655	Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Implantation in Patients With Brugada Syndrome. **2019**, 5, 141-148		11
654	A personalized approach to long QT syndrome. **2019**, 34, 46-56		9
653	Ventricular tachycardia in the absence of structural heart disease. **2019**, 105, 645-656		4
652	Challenge and Impact of Quinidine Access in Sudden Death Syndromes: A National Experience. **2019**, 5, 376-382		12
651	Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility. **2019**, 40, 842-853		19
650	German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. **2019**, 108, 577-599		11
649	Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. **2019**, 28, 22-30		64
648	Treatment of ventricular arrhythmias: What's New?. **2019**, 29, 249-261		11
647	Prevalence of early repolarization syndrome and long-term clinical outcome in patients with the diagnosis of idiopathic ventricular fibrillation. **2019**, 34, 625-631		6
646	Recommendations for the use of electrophysiological study: Update 2018. **2019**, 60, 82-100		10
645	Emerging Implications of Genetic Testing in Inherited Primary Arrhythmia Syndromes. **2019**, 27, 23-33		8
644	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. *Heart Rhythm*, **2020**, 17, e2-e154	6.7	80
643	Brugada syndrome with SCN5A mutations exhibits more pronounced electrophysiological defects and more severe prognosis: A meta-analysis. **2020**, 97, 198-208		9
642	Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity. **2020**, 45, 142-157		3
641	Caring for the pregnant woman with an inherited arrhythmia syndrome. *Heart Rhythm*, **2020**, 17, 341-348	6.7	16
640	Making the case for cascade screening among families with inherited heart disease. *Heart Rhythm*, **2020**, 17, 113-114	6.7	3
639	Epidemiology of inherited arrhythmias. **2020**, 17, 205-215		18

638	Pharmacological activation of IKr in models of long QT Type 2 risks overcorrection of repolarization. **2020**, 116, 1434-1445		11
637	Catheter ablation for monomorphic ventricular tachycardia in Brugada syndrome patients: detailed characteristics and long-term follow-up. **2020**, 57, 97-103		1
636	Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy. *Heart Rhythm*, **2020**, 17, 106-112	6.7	6
635	Contraction alterations in Brugada syndrome; association with life-threatening ventricular arrhythmias. **2020**, 299, 147-152		13
634	Clinical and genetic investigation of catecholaminergic polymorphic ventricular tachycardia in a consanguineous Tunisian family. **2019**, 1-4		1
633	Mortality risk of early repolarization pattern. **2020**, 43, 169-171		
632	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. **2020**, 220, 213-223		5
631	"Nonsignificant" early repolarization pattern on postresuscitation ECG as a harbinger of impending electrical storm. **2020**, 25, e12686		2
630	The merits of the ICD for inherited heart rhythm disorders: A critical re-appraisal. **2020**, 30, 415-421		1
629	The ketogenic diet and the QT interval. **2020**, 33, 77-79		3
628	Improving long QT syndrome diagnosis by a polynomial-based T-wave morphology characterization. *Heart Rhythm*, **2020**, 17, 752-758	6.7	10
627	Clinical and genetic evaluation after sudden cardiac arrest. **2020**, 31, 570-578		4
626	Brugada Syndrome: Clinical Care Amidst Pathophysiological Uncertainty. **2020**, 29, 538-546		2
625	Sĥdrome de Brugada inducido por flecainida. **2020**, 2, 100037		0
624	Age at diagnosis of Brugada syndrome: Influence on clinical characteristics and risk of arrhythmia. *Heart Rhythm*, **2020**, 17, 743-749	6.7	16
623	50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - Time to Explore the Dark Side of the Moon. **2020**, 29, 520-528		8
622	Genetic Testing in Inherited Heart Diseases. **2020**, 29, 505-511		14
621	Number of electrocardiogram leads in the diagnosis of spontaneous Brugada syndrome. **2020**, 113, 152-158		

620	Discovery of Digenic Mutation, KCNH2 c.1898A >C and JUP c.916dupA, in a Chinese Family with Long QT Syndrome via Whole-Exome Sequencing. **2020**, 4, 257-267	
619	[Particularities of African descent patient's electrocardiogram]. **2020**, 69, 289-293	1
618	Secondary prevention of sudden cardiac death. **2020**, 1, 297-310	
617	Recurrent Cardiac Arrest With Negative Stress Test: An Unusual Presentation of Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 2, 1178-1181	
616	Electrical storm in a febrile patient with Brugada syndrome and COVID-19 infection. **2020**, 6, 676-679	4
615	Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 28, 325-331	6
614	Prognostic significance of a low T/R ratio in Brugada syndrome. **2020**, 63, 6-11	1
613	Brugada syndrome. **2021**, 76, 805-824	0
612	Scared to death-A novel mutation in catecholaminergic polymorphic ventricular tachycardia. **2020**, 6, 268-271	
611	Video game ventricular tachycardia: The "Fortnite" phenomenon. **2020**, 6, 313-317	0
610	Suppression of cardiac memory-related severe form of torsades de pointes by landiolol in a patient with congenital long QT syndrome type 2. **2020**, 6, 407-410	0
609	Elective implantable cardioverter-defibrillator removal with extraction of leads following catheter ablation of idiopathic ventricular fibrillation and long-term surveillance. **2020**, 6, 464-468	1
608	Inherited cardiac arrhythmias. **2020**, 6, 58	53
607	New Insights on Genetic Diagnostics in Cardiomyopathy and Arrhythmia Patients Gained by Stepwise Exome Data Analysis. **2020**, 9,	2
606	QT interval duration and QT/heart rate relationship. **2020**, 97-116	
605	Sex and cardiac electrophysiology. **2020**, 421-427	1
604	Pregnancy in Congenital Long QT and Brugada syndrome patients. **2020**, 709-715	
603	Sudden infant death and electrophysiology abnormalities in young children. **2020**, 747-760	

602	[Why do we need genetics in cardiac rhythmology?]. **2020**, 31, 394-400	0
601	Clinical Implications and Gender Differences of KCNQ1 p.Gly168Arg Pathogenic Variant in Long QT Syndrome. **2020**, 9,	0
600	Genetic Loss of Causes Adrenergic-Induced Phase 3 Early Afterdepolariz ations and Polymorphic and Bidirectional Ventricular Tachycardia. **2020**, 13, e008638	4
599	. **2020**,	
598	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of -Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 142, 932-947	12
597	The Broad Spectrum of Cardiac Diseases: From Molecular Mechanisms to Clinical Phenotype. **2020**, 11, 761	18
596	Risk factors for recurrent ventricular arrhythmias in patients with idiopathic ventricular fibrillation. **2020**, 31, 2687-2688	
595	GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death. **2020**, 57, 102843	9
594	A high number of □atural□ mitochondrial DNA polymorphisms in a symptomatic Brugada syndrome type 1 patient. **2020**, 99, 1	3
593	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. **2020**, 36, 1847-1948	82
592	Sudden cardiac death in children with congenital heart disease: a critical review of the literature. **2020**, 30, 1559-1565	1
591	Risk and predictors of dyssynchrony cardiomyopathy in left bundle branch block with preserved left ventricular ejection fraction. **2020**, 43, 1494-1500	3
590	Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3. **2020**, 11, 1182	4
589	Prevalence of Abnormal Heart Weight After Sudden Death in People Younger than 40 Years of Age. **2020**, 9, e015699	3
588	Propranolol Attenuates Late Sodium Current in a Long QT Syndrome Type 3-Human Induced Pluripotent Stem Cell Model. **2020**, 8, 761	4
587	Systematic Evaluation of Variant Using ACMG/AMP Guidelines and Risk Stratification in Long QT Syndrome Type 1. **2020**,	0
586	The appearance of a single left atrial tachycardia as two different types on preoperative surface and intracardiac ECG of pacemaker due to progressive cardiac conduction disturbance. **2020**, 8, 1534-1537	1
585	Electrocardiography of Inherited Arrhythmias and Cardiomyopathies. **2020**,	

584	Susceptibility to Ventricular Arrhythmias Resulting from Mutations in , , and Evaluated in hiPSC Cardiomyocytes. **2020**, 2020, 8842398	4
583	Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess phenotype, behavioural and psychosocial outcomes. **2020**, 28, 1486-1496	5
582	Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. **2020**, 142, e214-e233	35
581	Functional coculture of sympathetic neurons and cardiomyocytes derived from human-induced pluripotent stem cells. **2020**, 319, H927-H937	11
580	Prevalence and Clinical Significance of Latent Brugada Syndrome in Atrial Fibrillation Patients Below 45 Years of Age. **2020**, 7, 602536	
579	Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report. **2020**, 14, 238	1
578	Inherited Cardiac Arrhythmia Syndromes: Focus on Molecular Mechanisms Underlying TRPM4 Channelopathies. **2020**, 2020, 6615038	8
577	Electrocardiographic "Northwest QRS´Axis" in the Brugada Syndrome: A Potential Marker to Predict Poor Outcome. **2020**, 2, 2230-2234	2
576	Recommendations for genetic testing in cardiology: Review of major international guidelines. **2020**, 39, 597-610	0
575	Recommendations for genetic testing in cardiology: Review of major international guidelines. **2020**, 39, 597-610	
574	The trajectory of anxiety and depression in people presenting to a cardiac inherited disease service: a longitudinal study. **2021**, 36, 1260-1274	
573	Cardiac Transplantation for Refractory Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 2, 1757-1761	1
572	Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in Families. **2020**, 13, e002911	13
571	SIDS associated RYR2 p.Arg2267His variant may lack pathogenicity. **2020**, 60, 23-26	2
570	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. **2020**, 142, 324-338	27
569	Structures Illuminate Cardiac Ion Channel Functions in Health and in Long QT Syndrome. **2020**, 11, 550	11
568	Reclassification of genetic variants in children with long QT syndrome. **2020**, 8, e1300	6
567	Two-incision technique for the subcutaneous implantable cardioverter defibrillator. **2020**, 62, 736-738	

566	Genotype-Phenotype Correlation: A Triple DNA Mutational Event in a Boy Entering Sport Conveys an Additional Pathogenicity Risk. **2020**, 11,		10
565	Genome-wide association studies of cardiac electrical phenotypes. **2020**, 116, 1620-1634		4
564	Role of cardiac sympathetic denervation in ventricular tachycardia: A meta-analysis. **2020**, 43, 828-837		7
563	Evaluation of Clinical Practices Related to Variants of Uncertain Significance Results in Inherited Cardiac Arrhythmia and Inherited Cardiomyopathy Genes. **2020**, 13, e002789		5
562	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. **2020**, 22, 1147-1148		25
561	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.		11
560	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. *Heart Rhythm*, **2020**, 17, e269-e316	6.7	7
559	Bilateral cardiac sympathetic denervation in children with long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. **2020**, 61, 32-36		2
558	Structural Abnormalities on Cardiac Magnetic Resonance Imaging in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 6, 741-742		
557	How Will Genetics Inform the Clinical Care of Atrial Fibrillation?. **2020**, 127, 111-127		7
556	Left-ventricular innervation assessed by I-SPECT/CT is associated with cardiac events in inherited arrhythmia syndromes. **2020**, 312, 129-135		1
555	Handling of Ventricular Fibrillation in the Emergency Setting. **2019**, 10, 1640		4
554	High Prevalence of Late-Appearing T-Wave in Patients With Long QT Syndrome Type 8. **2020**, 84, 559-568		3
553	Outcomes in Brugada Syndrome Patients With Implantable Cardioverter-Defibrillators: Insights From the SGLT2 Registry. **2020**, 11, 204		6
552	When do athletes benefit from cardiac genetic testing?. **2020**, 54, 939-940		
551	Refractoriness to subcutaneous implantable cardioverter defibrillator after frequent therapies for ventricular fibrillation storms in a Brugada syndrome case. **2020**, 20, 134		1
550	A Review of Long QT Syndrome: Everything a Hospitalist Should Know. **2020**, 10, 369-375		2
549	Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia. **2020**, 598, 2817-2834		29

548	Brugada Syndrome: Oligogenic or Mendelian Disease?. **2020**, 21,		30
547	Diagnostic findings and follow-up outcomes in relatives to young non-autopsied sudden death victims. **2020**, 318, 61-66		2
546	High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel K11.1. *Heart Rhythm*, **2020**, 17, 2180-2189	6.7	12
545	The utility of drug challenge testing in Brugada syndrome: A systematic review and meta-analysis. **2020**, 31, 2474-2483		3
544	The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network. **2020**, 2, 652-662		3
543	Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. *Heart Rhythm*, **2020**, 17, 2145-2153	6.7	8
542	Yield and clinical significance of genetic screening in elite and amateur athletes. **2020**, 2047487320934265		16
541	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. **2020**, 59, 145-298		2
540	Variant Frequency and Clinical Phenotype Call Into Question the Nature of Minor, Nonsyndromic Long-QT Syndrome-Susceptibility Gene-Disease Associations. **2020**, 141, 495-497		7
539	Wide QRS complex and the risk of major arrhythmic events in Brugada syndrome patients: A systematic review and meta-analysis. **2020**, 36, 143-152		3
538	Cardiac phenotype in propionic acidemia - Results of an observational monocentric study. **2020**, 130, 41-48		9
537	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 13, e007471		4
536	Catecholaminergic polymorphic ventricular tachycardia due to RyR2 mutation: recreational cycling as a trigger of lethal arrhythmias. **2020**, 16, 466-470		1
535	Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family. **2020**, 8, e1151		2
534	The evolution of gene-guided management of inherited arrhythmia syndromes: Peering beyond monogenic paradigms towards comprehensive genomic risk scores. **2020**, 31, 2998-3008		1
533	Reevaluating the Mutation Classification in Genetic Studies of Bradycardia Using ACMG/AMP Variant Classification Framework. **2020**, 2020, 2415850		0
532	Intentional nontherapy in long QT syndrome. *Heart Rhythm*, **2020**, 17, 1147-1150	6.7	6
531	Time to Rethink the Genetic Architecture of Long QT Syndrome. **2020**, 141, 440-443		3

530	Initially unexplained cardiac arrest in children and adolescents: A national experience from the Canadian Pediatric Heart Rhythm Network. *Heart Rhythm*, **2020**, 17, 975-981	6.7	14
529	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. **2020**, 141, 429-439		15
528	Catheter and Device Management of Inherited Cardiac Conditions. **2020**, 29, 594-606		0
527	Second opinion system for sudden cardiac death cases in forensic practice. **2020**, 134, 1255-1263		7
526	Utility of genetic testing in athletes. **2020**, 43, 915-920		5
525	Cardiogenetics: a primer for the clinical cardiologist. **2020**, 106, 938-947		3
524	Cardiac arrhythmias in pregnant women: need for mother and offspring protection. **2020**, 36, 1225-1243		3
523	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. *Heart Rhythm*, **2020**, 17, 1456-1462	6.7	115
522	Heritable arrhythmias associated with abnormal function of cardiac potassium channels. **2020**, 116, 1542-1556		7
521	Understanding the personal and community impact of long QT syndrome: A perspective from Gitxsan women. **2020**, 29, 562-573		1
520	Post-operative Brugada electrocardiographic pattern, polymorphic ventricular tachycardia, and sudden death in a child after administration of propofol anaesthesia. **2020**, 30, 724-727		3
519	Lithium Toxicity from the Addition of an ACE Inhibitor with an Unexpected Type I Brugada Pattern ECG: Case Files of the Medical Toxicology Fellowship at the University of California, San Diego. **2020**, 16, 321-328		1
518	Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death. **2020**, 145, 413-420		4
517	COVID-19 Infection Unmasking Brugada Syndrome. **2020**, 6, 237-240		45
516	Precision medicine in cardiac electrophysiology: where we are and where we need to go. **2020**, 5, 165-180		
515	Symptoms and healthcare contact preceding sudden cardiac death in persons aged 1-49 years. **2021**, 31, 119-124		2
514	Multiallelic rare variants support an oligogenic origin of sudden cardiac death in the young. **2021**, 46, 94-102		4
513	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic. **2021**, 190, 403-409		4

512	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. **2021**, 23, 147-148		18
511	Changes in genetic variant results over time in pediatric cardiomyopathy and electrophysiology. **2021**, 30, 229-236		3
510	"Concealed cardiomyopathy" as a cause of previously unexplained sudden cardiac arrest. **2021**, 324, 96-101		6
509	Muerte súbita de jóvenes: rendimiento diagnóstico de un programa autonómico de autopsia molecular con secuenciación masiva. **2021**, 74, 402-413		3
508	Peripartum management of a patient with catecholaminergic polymorphic ventricular tachycardia. **2021**, 26, e12796		2
507	Sudden cardiac death in persons aged 50 years or younger: diagnostic yield of a regional molecular autopsy program using massive sequencing. **2021**, 74, 402-413		3
506	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. *Heart Rhythm*, **2021**, 18, e1-e50	6.7	37
505	Sex-specific I activation in rabbit ventricles with drug-induced QT prolongation. *Heart Rhythm*, **2021**, 18, 88-97	6.7	3
504	Is Exercise Helpful or Harmful in Dealing With Specific Arrhythmia. **2021**, 46, 100740		1
503	Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. **2021**, 42, 1687-1695		13
502	RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. **2021**, 128, 321-331		13
501	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. **2021**, 37, 481-534		3
500	Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. **2021**, 323, 100-105		5
499	Challenges and opportunities for integrating genetic testing into a diagnostic workflow: heritable long QT syndrome as a model. **2021**, 8, 17-26		
498	The link between abnormalities of calcium handling proteins and catecholaminergic polymorphic ventricular tachycardia. **2021**, 33, 323-331		1
497	Cardiac Issues in Football. **2021**, 285-310		
496	Spatiotemporal differences in precordial electrocardiographic amplitude before and after flecainide provocation are associated with a history of unstable ventricular arrhythmia in Brugada syndrome. **2021**, 32, 758-765		
495	Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?. **2021**, 42, 1073-1081		17

494	Brugada Syndrome: Anesthesia Management. **2021**, 09, 147-153	
493	Pathogenesis and drug response of iPSC-derived cardiomyocytes from two Brugada syndrome patients with different Na 1.5-subunit mutations. **2021**, 35, 395-407	0
492	Potential overdiagnosis of long QT syndrome using exercise stress and QT stand testing in children and adolescents with a low probability of disease. **2021**, 32, 500-506	1
491	Risk stratification in Brugada syndrome: the challenge of the grey zone. **2021**, 42, 1696-1697	4
490	Calmodulinopathy in inherited arrhythmia syndromes. **2021**, 33, 339-344	
489	High-risk atrioventricular block in Brugada syndrome patients with a history of syncope. **2021**, 32, 772-781	0
488	Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. **2021**,	0
487	Long QT syndrome - Bench to bedside. **2021**, 2, 89-106	1
486	Territory-Wide Chinese Cohort of Long QT Syndrome: Random Survival Forest and Cox Analyses. **2021**, 8, 608592	6
485	Day-to-Day Variation of Early Repolarization Pattern Predicts Life-Threatening Arrhythmias in Patients With Brugada Syndrome. **2021**, 85, 300-308	0
484	Long-term prognosis in patients with non-type 1 Brugada electrocardiogram: Results from a large Japanese cohort of idiopathic ventricular fibrillation. **2021**, 26, e12831	1
483	Patch monitors for arrhythmia monitoring in patients for suspected inherited arrhythmia syndrome. **2021**, 32, 856-859	0
482	Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?. **2021**, 128, 332-334	1
481	Will I Die From Brugada Syndrome?: The Rumination of Risk Stratification. **2021**, 7, 223-225	0
480	Genetic Factors Underlying Sudden Infant Death Syndrome. **2021**, 14, 61-76	3
479	Outcomes of Pediatric Patients With Defibrillators Following Initial Presentation With Sudden Cardiac Arrest. **2021**, 14, e008517	0
478	A case report of a young patient with both Brugada and long QT3 syndrome: between the hammer and the anvil. **2021**, 5, ytab053	1
477	Sex-Related Differences in Cardiac Channelopathies: Implications for Clinical Practice. **2021**, 143, 739-752	10

476	Electroimmunology and cardiac arrhythmia. **2021**, 18, 547-564		5
475	Short coupled torsade de pointes: Critical timing of the ventricular premature beats. **2021**, 65, 69-72		0
474	Long QT syndrome type 2: mechanism-based therapies. **2021**, 17, 1453-1463		
473	Recurrent exercise-induced ventricular tachycardia in a patient with Brugada syndrome. **2021**, 7, 144-147		
472	Poor prognosis in young patients with atrioventricular block of unknown aetiology: who is to blame? The physician or the pacemaker?. **2021**, 42, 2069-2071		1
471	Mexiletine Shortened QT Interval and Reduced Ventricular Arrhythmias in a Pedigree of Type 2 Long QT Syndrome Combined with Left Ventricular Non-Compaction. **2021**, 62, 427-431		2
470	Human pluripotent stem cell-based cardiovascular disease modeling and drug discovery. **2021**, 473, 1087-1097		2
469	The frequency spectrum of sympathetic nerve activity and arrhythmogenicity in ambulatory dogs. *Heart Rhythm*, **2021**, 18, 465-472	6.7	2
468	Artificial Intelligence-Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device. **2021**, 143, 1274-1286		18
467	Prevented Sudden Cardiac Death and Neurologic Recovery in Inherited Heart Diseases. **2021**, 8, 634300		
466	Arrhythmic risk during pregnancy and postpartum in patients with long QT syndrome. **2021**, 32, 180-185		2
465	Functional testing for variant prioritization in a family with long QT syndrome. **2021**, 296, 823-836		0
464	SUDEP - more attention to the heart? A narrative review on molecular autopsy in epilepsy. **2021**, 87, 103-106		2
463	Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia. **2021**, 7, 437-441		1
462	Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success. **2021**, 32, 199-206		0
461	Whole-Exome Sequencing Identifies a Novel Mutation in a Chinese Family with Atrioventricular Block. **2021**, 2021, 9247541		3
460	Suppression-Replacement Gene Therapy for Type 1 Long QT Syndrome. **2021**, 143, 1411-1425		3
459	Hyperthyroidism precipitating cardiac arrest in a patient with Brugada pattern. **2021**, 14,		1

458	Propofol for Induction and Maintenance of Anesthesia in Patients With Brugada Syndrome: A Single-Center, 25-Year, Retrospective Cohort Analysis. **2021**, 132, 1645-1653	1
457	Abnormal Cardiac Repolarization After Seizure Episodes in Structural Brain Diseases: Cardiac Manifestation of Electrical Remodeling in the Brain?. **2021**, 10, e019778	1
456	Clinical significance of inferolateral early repolarisation and late potentials in children with Brugada Syndrome. **2021**, 66, 79-83	1
455	Diagnosis, management and therapeutic strategies for congenital long QT syndrome. **2021**,	11
454	A novel variant in associated with short QT syndrome. **2021**, 7, 650-654	
453	Precision Medicine Approaches to Cardiac Arrhythmias: JACC Focus Seminar 4/5. **2021**, 77, 2573-2591	3
452	Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment. **2021**, 21, e456-e459	
451	Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. **2021**, 42, 2827-2838	18
450	Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death. **2021**, 18, 774-784	1
449	Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes: JACC Focus Seminar 1/5. **2021**, 77, 2517-2530	2
448	Inherited arrhythmia syndrome predisposing to sudden cardiac death. **2021**, 36, 527-538	4
447	Electrical storm: Prognosis and management. **2021**, 66, 70-79	1
446	Electrocardiographic Abnormalities and Mortality in Epilepsy Patients. **2021**, 57,	1
445	Bilateral thoracoscopic sympathectomy for cardiac denervation in pediatric population: Does Kuntz nerve cauterization have an impact on success?. **2021**, 36, 2705-2713	0
444	The smartwatch detects ECG abnormalities typical of Brugada syndrome. **2021**, 22, e24-e25	1
443	Monogenic and Polygenic Contributions to QTc Prolongation in the Population.	1
442	JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. **2021**, 85, 1104-1244	17
441	Clinical and Functional Genetic Characterization of the Role of Cardiac Calcium Channel Variants in the Early Repolarization Syndrome. **2021**, 8, 680819	2

440	Identification of genes associated with sudden cardiac death: a network- and pathway-based approach. **2021**, 13, 3610-3627	
439	Targeting of Potassium Channels in Cardiac Arrhythmias. **2021**, 42, 491-506	4
438	Clinical Characteristics of p.R965C Carriers: A Common Founder Variant Predisposing to Brugada Syndrome in Thailand. **2021**, 14, e003229	0
437	The Heart in Diabetic Ketoacidosis: A Narrative Review Focusing on the Acute Cardiac Effects and Electrocardiographic Abnormalities. **2021**, 361, 690-701	1
436	Parahisian pacing to unmask Brugada pattern with concomitant left bundle branch block and to document epicardial ablation endpoint in Brugada syndrome. **2021**, 7, 382-385	1
435	Sudden Death in the Young: Information for the Primary Care Provider. **2021**, 148,	6
434	A consistent arrhythmogenic trait in Brugada syndrome cellular phenotype. **2021**, 11, e413	0
433	Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. **2021**, 42, 2854-2863	4
432	Lithium-induced ECG modifications: navigating from acute coronary syndrome to Brugada syndrome. **2021**, 14,	3
431	Does the Age of Sudden Cardiac Death in Family Members Matter in Brugada Syndrome?. **2021**, 10, e019788	5
430	Diagnostic Impact of Repeated Expert Review & Long-Term Follow-Up in Determining Etiology of Idiopathic Cardiac Arrest. **2021**, 10, e019610	3
429	Right ventricular function and dyssynchrony in Brugada syndrome: Highlighting the importance of the mechanical substrate in the right ventricular outflow tract. **2021**, 333, 233-238	2
428	JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. **2021**, 37, 709-870	22
427	Risk stratification of patients with Brugada syndrome: the impact of myocardial strain analysis using cardiac magnetic resonance feature tracking. **2021**, 62, 329-338	2
426	Electrocardiogram in Pediatric Syncope: Practice Variation Among Pediatric Emergency Physicians. **2021**,	
425	Personalized medicine in cardiovascular disease: review of literature.. **2021**, 20, 1793-1805	1
424	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. **2021**, 11,	1
423	Early Identification of Prolonged QT Interval for Prevention of Sudden Infant Death. **2021**, 9, 704580	1

422	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Executive summary. **2021**, 21, 349-366		1
421	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC) Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhy. **2021**, 7, 1437-1472		2
420	Brugada pattern in an afebrile patient with acute COVID-19. **2021**, 14,		2
419	Common variants in SCN10A gene associated with Brugada syndrome. **2021**,		0
418	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. *Heart Rhythm*, **2021**, 18, 1888-1924	6.7	10
417	Management of Congenital Long-QT Syndrome: Commentary From the Experts. **2021**, 14, e009726		2
416	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. **2021**, 21, 367-393		1
415	Defining idiopathic ventricular fibrillation: A systematic review of diagnostic testing yield in apparently unexplained cardiac arrest. *Heart Rhythm*, **2021**, 18, 1178-1185	6.7	0
414	Efficacy of a Subcutaneous Implantable Cardioverter Defibrillator in a Child with Early Repolarization Syndrome. **2021**, 62, 919-923		
413	Extrinsic sex hormones rather than gender itself contribute directly to the electrocardiographic phenotype. *Heart Rhythm*, **2021**, 18, 1210-1211	6.7	
412	J wave syndromes: What's new?. **2021**,		1
411	Role of fragmented QRS and Shanghai score system in recurrence of ventricular fibrillation in patients with early repolarization syndrome. **2021**, 26, e12873		3
410	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. **2021**, 31, 1717-1737		0
409	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2021**, 18, 1825-1832	6.7	3
408	A Massively Parallel Trafficking Assay Accurately Predicts Loss of Channel Function in KCNH2 Variants.		0
407	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Executive Summary. *Heart Rhythm*, **2021**, 18, 1925-1950	6.7	2
406	Hyponatremia induced Brugada syndrome mimicking ST segment elevation myocardial infarction. **2021**, 37, 1377-1379		
405	Dose response to nadolol in congenital long QT syndrome. *Heart Rhythm*, **2021**, 18, 1377-1383	6.7	2

404	The effect of statins on RyR and RyR-associated disease. **2021**, 131, 661-671		2
403	Endophenotype Effect Sizes Provide Evidence Supporting Variant Pathogenicity in Monogenic Disease Susceptibility Genes.		
402	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare Variants. **2021**, 14, e003289		0
401	Who is at high-risk in J wave syndromes?. **2021**,		
400	Diffuse ST-Segment Elevation With Idiopathic Malignant Ventricular Arrhythmia. **2021**, 144, 399-402		0
399	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. **2021**, 42, 3427-3520		134
398	Brugada ECG Pattern - A Blip on the Radar for a Pontentially Life-Threatening Condition. **2021**, 117, 350-351		
397	A Deep Learning-enabled Electrocardiogram Model for the Identification of a Rare Inherited Arrhythmia: Brugada Syndrome. **2021**,		1
396	Process of Care and a Practical Toolkit for Evaluating and Managing Arrhythmic Risk in the Cardiogenetic Pregnant Patient. **2021**,		
395	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. **2021**, 31, 1738-1769		1
394	Genomic Autopsy of Sudden Deaths in Young Individuals. **2021**, 6, 1247-1256		2
393	Advances in the Molecular Genetics of Catecholaminergic Polymorphic Ventricular Tachycardia. **2021**, 12, 718208		2
392	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. **2021**,		6
391	Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association. **2021**, 14, e000086		6
390	Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist. **2021**, 22,		4
389	The Propagation of Racial Disparities in Cardiovascular Genomics Research. **2021**, 14, e003178		1
388	Role of subcutaneous implantable loop recorder for the diagnosis of arrhythmias in Brugada syndrome: A United Kingdom single-center experience. *Heart Rhythm*, **2021**,	6.7	3
387	Evaluation of the Seattle and International Criteria in elite Nigerian athletes. **2021**, 68, 14-23		0

386	Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis. **2021**, 32, 3057-3067		4
385	dST-Tiso Interval, a Novel Electrocardiographic Marker of Ventricular Arrhythmia Inducibility in Individuals With Ajmaline-Induced Brugada Type I Pattern. **2021**, 159, 94-99		3
384	Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. **2021**, 8, 730161		3
383	Recurrent Pregnancy Loss and Concealed Long-QT Syndrome. **2021**, 10, e021236		2
382	Long QT syndrome with potassium voltage-gated channel subfamily H member 2 gene mutation mimicking refractory epilepsy: case report. **2021**, 21, 338		1
381	Skin sympathetic nerve activity as a biomarker of fitness. *Heart Rhythm*, **2021**, 18, 2169-2176	6.7	0
380	Dopamine in Idiopathic Polymorphic Ventricular Tachycardia/Ventricular Fibrillation. **2021**, 12, 4699-4703		1
379	Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention. **2021**, 13, 523-530		2
378	Brugada Pattern in a Child with Severe SARS-CoV-2 Related Multisystem Inflammatory Syndrome. **2021**, 13, 504-510		1
377	Anesthesia for Long QT Syndrome. 1		
376	Long QT Syndrome. **2021**, 374-385		
375	Genetic counseling of ventricular tachycardias. **2021**, 25, 675-676		
374	Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. **2021**,		9
373	Genetic markers of vasovagal syncope. **2021**, 235, 102871		0
372	Mechanisms, Diagnosis, and Therapy of Cardiac Arrhythmia. **2022**, 319-327		
371	Cardiac K Channels and Channelopathies. **2021**, 267, 113-138		2
370	Symptomatic Long QT Syndrome Coexisting with Asymptomatic Acetylcholine-induced Vasospasm. **2021**, 60, 2085-2088		
369	Cardiovascular Disease. **2021**, 583-594		0

368	The Cardiovascular System. **2015**, 481-529	1
367	History of the J Wave and J Wave Syndromes. **2016**, 1-14	1
366	Long QT Syndrome. **2016**, 155-173	1
365	Cardiac Arrhythmogenesis During Sleep. **2017**, 1237-1242.e4	4
364	QTc interval, cardiovascular events and mortality in patients with atrial fibrillation. **2018**, 252, 101-105	9
363	Autonomic Modulation of Cardiac Arrhythmias: Methods to Assess Treatment and Outcomes. **2020**, 6, 467-483	17
362	Ablation for the treatment of Brugada syndrome: current status and future prospects. **2020**, 17, 123-130	4
361	Association of vitamin D deficiency with arterial stiffness in newly diagnosed hypertension. **2021**, 26, 113-117	2
360	Catecholaminergic Polymorphic Ventricular Tachycardia. **2017**, 33, 427-431	5
359	Inpatient detection of cardiac-inherited disease: the impact of improving family history taking. **2016**, 3, e000329	12
358	Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association. **2020**, 141, e654-e685	55
357	KCND3 potassium channel gene variant confers susceptibility to electrocardiographic early repolarization pattern. **2019**, 4,	5
356	Non-diagnostic autopsy findings in sudden unexplained death victims. **2020**, 20, 58	4
355	Clinical and genetic diagnosis for inherited cardiac arrhythmias. **2014**, 81, 203-10	3
354	Calmodulin 2 Mutation N98S Is Associated with Unexplained Cardiac Arrest in Infants Due to Low Clinical Penetrance Electrical Disorders. **2016**, 11, e0153851	18
353	GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOL study": Lack of common variants with large effect sizes. **2017**, 12, e0181875	10
352	Neuroleptic-Induced Brugada Syndrome - A Case Report. 5,	1
351	Early Repolarisation - What Should the Clinician Do?. **2015**, 4, 96-9	4

350	Brugada Syndrome and Early Repolarisation: Distinct Clinical Entities or Different Phenotypes of the Same Genetic Disease?. **2016**, 5, 84-9	1
349	The Atrial Phenotype of the Inherited Primary Arrhythmia Syndromes. **2019**, 8, 42-46	1
348	British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication. **2019**, 8, 161-165	8
347	. **2018**, 58, 52-58	1
346	The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes. **2018**, 9, 2996-3005	2
345	A Pooled Analysis of the Prognostic Significance of Brugada Syndrome with Atrial Fibrillation. **2020**, 26, 129-137	1
344	The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome. **2015**, 112, 394-401	19
343	Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies. **2019**, 40, 187-200	4
342	Precision Population Medicine in Primary Care: The Sanford Chip Experience. **2021**, 12, 626845	6
341	Masked inherited primary arrhythmia syndromes in sudden cardiac death patients accompanied by coronary vasospasm. **2017**, 32, 836-846	2
340	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death. **2016**, 90, 115-120	2
339	Palpitations and Arrhythmias and Sudden Cardiac Arrest/Sudden Cardiac Death in Children and Adolescents. **2015**, 44, e279-86	1
338	Brugada Syndrome:Risk Stratification And Management. **2016**, 9, 1507	4
337	Type 1 Brugada pattern electrocardiogram induced by hypokalemia. **2016**, 5, 709-711	4
336	Brugada syndrome in children - Stepping into unchartered territory. **2017**, 10, 248-258	12
335	A Report of Brugada Syndrome Presenting with Cardiac Arrest Triggered by Verapamil Intoxication. **2017**, 34, 576-579	2
334	Genetic analysis of cardiac SCN5A Gene in Iranian patients with hereditary cardiac arrhythmias. **2016**, 16, 170-4	2
333	Short QT syndrome in a 14-year-old patient: The first pediatric case from Turkey. **2015**, 15, 590-1	4

332	A rare cause of sudden cardiac arrest: Catecholaminergic polymorphic ventricular tachycardia. **2018**, 53, 124-128	4
331	Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study. **2014**, 25, 176-84	11
330	Brugada Pattern Type 2 Diagnosis Unmasked by Aspiration Pneumonia. **2020**, 12, e8331	1
329	A Japanese Family with Long QT Syndrome: Distinct Genetic and Phenotypic Features in Children of Asymptomatic Parents with SCN5A and KCNQ1 Mutations. **2017**, 33, 431-437	1
328	Une syncope lors d□n match de football. **2021**, 2, 643-643	
327	Ventricular fibrillation ablation in cardiomyopathies and arrhythmic storm. **2021**, 23, E112-E117	1
326	Intravenous lidocaine in malignant long QT type 3: A´bridge over troubled waters. *Heart Rhythm*, **2021**,	6.7
325	Biventricular Myocardial Fibrosis and Sudden Death in Patients With Brugada´Syndrome. **2021**, 78, 1511-1521	1
324	Proteomic Analysis of the Functional Inward Rectifier Potassium Channel (Kir) 2.1 Reveals Several Novel Phosphorylation Sites. **2021**, 60, 3292-3301	0
323	Brugada syndrome: update and future perspectives. **2021**,	1
322	Dynamic Electrocardiogram under P Wave Detection Algorithm Combined with Low-Dose Betaloc in Diagnosis and Treatment of Patients with Arrhythmia after Hepatocarcinoma Resection. **2021**, 2021, 6034180	1
321	Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation. **2021**, 69, 111-118	1
320	Rare giant T-wave inversions associated with myocardial stunning: report of 2 cases. **2014**, 93, e39	
319	????????. **2015**, 35, 165-167	1
318	Next generation sequencing for molecular confirmation of hereditary sudden cardiac death syndromes. **2015**, 85, 68-72	0
317	Early Repolarization Syndrome. **2015**, 1-9	
316	Early Repolarisation Syndrome - New Concepts. **2015**, 4, 169-71	
315	Genetic Disorders of the Cardiac Impulse. **2015**, 267-295	

314	Acute Management of Arrhythmias in Patients with Channelopathies. **2016**, 117-128	
313	Similarities and Differences in the Electrocardiographic and Clinical Features Between Early Repolarization Syndrome and Brugada Syndrome. **2016**, 233-244	
312	Type 1 Brugada Pattern Unmasked During the Recovery Period of an Exercise Stress Test. **2016**, 106, 447-9	4
311	The role of cardiologist and surgeon in the treatment of patients with Brugada syndrome. **2016**, 9, 87	1
310	Catecholaminergic Polymorphic Ventricular Tachycardia. **2016**, 557-563	
309	Long QT Syndrome: Congenital. **2016**, 807-818	
308	Prevalence and Risk Stratification of Patients with Electrocardiographic Pattern of Early Repolarization. **2016**, 193-206	
307	Prevalence and Clinical Characteristics of Brugada Syndrome. **2016**, 121-138	
306	Catecholaminergic Polymorphic Ventricular Tachycardia. **2016**, 193-200	1
305	Short QT Syndrome (SQTS). **2016**, 1117-1124	
304	Idiopathic Ventricular Fibrillation. **2016**, 211-225	
303	Risk Stratification in Brugada Syndrome: Clinical Characteristics, Electrocardiographic Parameters and Auxiliary Testing. **2016**, 173-191	
302	Brugada Syndrome. **2016**, 319-331	
301	Malignant Dysrhythmias - Brugada Type 1 Pattern Formation in the Presence of Fever. **2016**, 1, 5072	
300	Brugada syndrome – first results of ajmaline testing. **2016**, 11, 437-437	
299	Brugada syndrome - where do we stand today - case reports. **2016**, 11, 425-425	
298	Single Screening Failed to Exclude the Candidate of Subcutaneous Implantable Cardioverter Defibrillator in Patient with Brugada Syndrome. **2017**, 37, 243-254	
297	Anaesthetic Management in Brugada Syndrome - A Case Report. **2017**, 11, UD03-UD04	1

296	Het elektrocardiogram van erfelijke hartziektes, erfelijke ritmestoornissen en cardiomyopathie?n. **2017**, 221-242	
295	?????????. **2017**, 25, 14-21	
294	Efficacy of Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia. **2017**, 33, 66-68	
293	Leitsymptom Fieber. **2017**, 239-263	
292	Long QT Syndrome with Palmar Hyperhidrosis Treated with Endoscopic Thoracic Sympathectomy. **2017**, 33, 326-331	
291	Brugada Syndrome with Spontaneous Fluctuation in ECG Pattern. **2017**, 11, OJ01	1
290	Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies. **2017**, 8, 2613-2622	2
289	Epidemiology, Prevalence of J Wave, and Early Repolarization Syndrome. **2018**, 1-11	
288	Acute and Chronic Pharmacological Therapy for ERS. **2018**, 97-107	
287	ERS in Relation to Brugada Syndrome. **2018**, 43-54	
286	An Overview of Diagnosis and Management Strategies for Long QT Syndrome. **2017**, 8, 2750-2757	1
285	Fever Induced Brugada Syndrome. **2017**, 2, 024-025	
284	K□perliche Aktivit□, Sport, Genetik und kardiovaskul□re Erkrankungen. **2018**, 391-417	
283	Natural history of idiopathic ventricular arrhythmias in children. **2017**, 3, 4-8	
282	Genetics of Long QT and Short QT Syndromes. 1-6	
281	Can documented coronary vasospasm be the smoking gun in settling the etiology of sudden cardiac death?. **2017**, 32, 816-818	1
280	Long QT Syndrome. **2018**, 351-356	
279	Ion Channelopathy Genetics. **2018**, 132-144	

278 ?????????????. **2018**, 26, 55-63

277 ?????????????????????????. **2018**, 26, 70-78

276 Catecholaminergic Polymorphic Ventricular Tachycardia. **2018**, 231-256

275 Brugada Syndrome: Current Perspectives. **2018**, 187-214

274 Inherited Arrhythmias: Brugada Syndrome and Early Repolarisation Syndrome. **2018**, 437-480

273 Inherited Arrhythmias: LQTS/SQTS/CPVT. **2018**, 413-435

272 Genetics and Genomics of Sudden Unexplained Cardiac Death. **2018**, 755-779

271 Transgenic Animal Models of Cardiac Channelopathies: Benefits and Limitations. **2018**, 379-420 0

270 OBSOLETE: Electrophysiology Approaches for Ventricular Tachycardia. **2018**,

269 Cohort of Patients Referred for Brugada Syndrome Investigation in an Electrophysiology Service - 19-Year Registry. **2018**, 111, 19-20 1

268 7. Diagnosis and Therapy in Inherited Arrhythmias. **2018**, 107, 521-526

267 Left Main Coronary Artery Stenosis Presenting as Syncope with Brugada Type Electrocardiography. **2018**, 19, 22-25

266 Assessing Candidacy for Primary Preventative Implantable Cardioverter-defibrillators in Pediatric Patients with Ion Channelopathies: Weighing the Risks and Benefits. **2018**, 9, 3297-3302

265 . **2018**, 58, 41-52 1

264 Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome. **2018**, 38, 269-276

263 Successful treatment of electrical storm in a child with early repolarization syndrome with orciprenaline and radiofrequency ablation. **2019**, 22, 94-96 0

262 The Role of Medical Therapy in Idiopathic Ventricular Fibrillation. **2019**, 5, 87 0

261 Turkish Society of Cardiology consensus report on recommendations for athletes with high-risk genetic cardiovascular diseases or implanted cardiac devices. **2019**, 22, 140-151

260	Brugada Syndrome: A Review. **2019**, 03, 235-252	
259	Exercise-induced syncope and Brugada syndrome. **2019**, 12, 292-294	3
258	Herzrhythmusstörungen bei Kindern und Jugendlichen. **2019**, 1-9	
257	Programmed Ventricular Stimulation in the Management of Brugada Syndrome Patients. **2019**, 112, 217-219	0
256	Premature Ventricular Contraction in Children. **2019**, 15, 435-446	1
255	Short QT Interval and Short QT Syndrome. **2019**, 35, 9-17	
254	KCND3 is a novel susceptibility locus for early repolarization.	0
253	Exercise Stress Tests in Arrhythmology. **2019**, 6, 5-14	
252	Síndrome de Brugada. Aspectos fisiopatológicos, clínicos y su asociación con enfermedades infecciosas. **2019**, 32, 217-231	1
251	Genetic Architecture, Pathophysiology, and Clinical Management of Brugada Syndrome. **2020**, 285-299	
250	Neuromodulation of Cardiac Repolarization and Arrhythmogenesis. **2020**, 49-76	
249	The Role of Inflammation and Autoimmunity in Long QT Syndrome. **2020**, 227-251	
248	Genetics, Molecular Biology, and Emerging Concepts of Early Repolarization Syndrome. **2020**, 255-268	
247	Rare but lethal short QT syndrome: most recent understanding of the disease. **2019**, 16, em154	
246	What is the Diagnosis?. **2019**, 32, 97-100	
245	Qual o Diagnóstico?. **2019**, 32, 97-100	
244	Brugada syndrome diagnosed after ventricular fibrillation with anamnesis of fever. **2019**, 61, 508-510	
243	Diagnosis and Management of Inherited Arrhythmias: Long- and Short-QT Syndromes, Catecholaminergic Polymorphic Ventricular Tachycardia, and Brugada Syndrome. **2019**, 35, 249-263	

242 Antiarrhythmic Medications. **2020**, 305-333

241 Early Repolarization Syndrome. **2020**, 51-65

240 Brugada Syndrome. **2020**, 25-39

239 Medical Evaluation of Athletes: Genetic Testing. **2020**, 203-221

238 High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KCNH2: Deep mutational scan of KCNH2 trafficking.

237 The implantable cardioverter defibrillator. **2020**, 315-356

236 The 10-Year Prognosis and Prevalence of Brugada-Type Electrocardiograms in Elderly Women: A Longitudinal Nationwide Community-Based Prospective Study. **2020**, 35, E25-E32 1

235 Idiopathic Ventricular Fibrillation: Diagnosis, Ablation of Triggers, Gaps in Knowledge, and Future Directions. **2020**, 11, 4135-4146 2

234 Surgical Approach in Congenital Long QT Interval Syndrome Patients. **2020**, 18, 63-69

233 Brugada Pattern Mimicking Myocardial Acute Infarct. **2020**, 33, 29-33

232 Sympathetic Denervation for Treatment of Ventricular Arrhythmias. **2020**, 13, 2404 2

231 Risk stratification in families with history of idiopathic ventricular fibrillation. **2020**, 6, 386-389

230 Dysrhythmia-Related Syndromes. **2020**, 193-200

229 Etiology of Sudden Death. **2021**, 17-35

228 Physical activity and aerobic fitness in children with inherited cardiac diseases. **2021**, 114, 727-736 0

227 Approach to inherited arrhythmias in pregnancy. **2021**, 100264

226 ICD shocks and complications in patients with inherited arrhythmia syndromes. **2021**, 37, 100908

225 Long QT Syndrome. **2020**, 3-24

224	Short QT Syndrome. **2020**, 41-50	
223	Comprehensive and Systematic Evaluation Following Unexplained Cardiac Arrest. **2020**, 211-214	
222	Brugada Syndrome: Clinical Features, Risk Stratification, and Management. **2020**, 21, 88-96	1
221	Bradycardias and Tachycardias: Acquired and Inheritable. **2020**, 109-123	
220	The Indication of Genetic Testing for the Children with Long QT Intervals. **2020**, 36, 344-345	
219	Clinical and genetic characteristics and course of congenital long QT syndrome in children: A nine-year single-center experience. **2021**, 25, 250-257	0
218	Prenatal Diagnosis and Preimplantation Genetic Testing for Inherited Cardiac Diseases. **2020**, 457-461	1
217	Long QT Syndrome. **2020**, 193-217	
216	Evaluation and Care of Common Pediatric Cardiac Disorders. **2021**,	
215	Leitsymptom Fieber. **2020**, 243-267	
214	Catecholaminergic Polymorphic Ventricular Tachycardia. **2020**, 775-790	
213	Short QT Syndrome. **2020**, 845-866	
212	Exercise stress tests in heart rhythm and conduction disturbances. **2020**, 13, 239	
211	Catecholaminergic Polymorphic Ventricular. **2020**, 247-257	
210	Clinical spectrum and long-term course of sustained ventricular tachycardia in pediatric patients: 10 years of experience. **2021**, 25, 313-322	1
209	Specific Populations: Paediatric and Adolescent Athletes. **2020**, 439-469	1
208	ECG Waves and Signs: Ionic and Cellular Basis. **2020**, 117-148	
207	Idiopathic Ventricular Fibrillation and Early Repolarization Syndrome. **2020**, 259-272	

206 J Wave Syndromes: Brugada and Early Repolarization Syndromes. **2020**, 745-774

205 Left sympathetic denervation as an effective therapy in a young patient with long QT syndrome. **2020**, 2, 95

204 Syncope in a 3-year-old male: A case report. **2020**, 11, 188-190

203 The Channelopathies and Sudden Death. **2020**, 267-289

202 Beta-blockers as Antiarrhythmic Agents. **2020**, 181-231

201 Can Right Ventricular Outlow Tract Monomorphic Ventricular Tachycardia Be Associated with Brugada Syndrome?. **2020**, 219-222

200 Role of electrocardiogram in diagnosis of inherited arrhythmia syndromes. **2020**, 71, 1-7

199 Herzrhythmusstörungen. **2020**, 2043-2051

198 Indications for Implantable Cardioverter Defibrillators. **2020**, 479-494

197 Congenital Long-QT Syndrome: From Genetics to Clinical Management. **2020**, 811-844

196 Sudden Cardiac Death in the Young: Post-mortem Investigation and Cardiogenetic Evaluation of Victims and Their Relatives. **2020**, 363-369

195 Electrocardiography in Athletes How to Identify High-risk Subjects. **2020**, 6, 24 0

194 Specific Cardiovascular Diseases and Competitive Sports Participation: Channelopathies. **2020**, 361-402

193 Clinical approach to the patient with Brugada Syndrome: risk stratification and optimal management. **2019**, 61, 473-485

192 Inherited Arrhythmia Syndromes. **2021**, 48, 1

191 Postcardioversion ST-segment changes. **2021**, 38, 854-866 0

190 Short QT Syndrome. **2022**, 139-150

189 Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. **2021**, 3

188	A Deep Learning-enabled Electrocardiogram Model for the Identification of a Rare Inherited Arrhythmia: Brugada Syndrome (Preprint).		
187	Early repolarization pattern and syndrome □horm or pathology?. **2020**, 38-41		
186	Evaluation Of Patients With Early Repolarization Syndrome. **2014**, 7, 1083		1
185	Silent and Malignant Early Repolarization Syndrome Mimicking Hyper-Acute ST Elevation Myocardial Infarction. **2016**, 32, 506-10		3
184	Extracorporeal Life Support as a Rescue Measure for Managing Life-Threatening Arrythmia and Brugada Syndrome. **2017**, 49, 312-316		
183	A study of the pathogenicity of variants in familial heart disease. The value of cosegregation. **2019**, 11, 1724-1735		2
182	Cardiac conduction defects. **2019**, 90, 20-29		13
181	Cardiovascular considerations for scuba divers. **2021**,		0
180	Histopathology of the Conduction System in Long QT Syndrome. **2021**, 1-15		0
179	Premature Ventricular Contraction-Triggered Ventricular Fibrillation and Sudden Cardiac Arrest in the Young.. **2022**, 8, 380-382		0
178	Confirmation of Cause of Death Via Comprehensive Autopsy and Whole Exome Molecular Sequencing in People With Epilepsy and Sudden Unexpected Death. **2021**, 10, e021170		1
177	The genetic basis of sudden death in young people - Cardiac and non-cardiac. **2021**, 810, 146067		
176	Characterization of Loss-Of-Function Mutations in Atypical Andersen Tawil Syndrome.. **2021**, 12, 773177		1
175	The role of CACNA1C in Brugada syndrome: prevalence and phenotype of probands referred for genetic testing.. *Heart Rhythm*, **2022**,	6.7	0
174	Risk stratification of syncope: Current syncope guidelines and beyond.. **2021**, 238, 102929		0
173	Clinical Advances in Congenital Long QT Syndrome. **2021**, 1, 195-201		0
172	Invariant Feature Extraction for CNN Classifier by using Gradient Reversal Layer. **2021**,		1
171	Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population.. **2022**, 10,		1

170 Unexplained syncope in a young athlete: the diagnostic process to find the diagnosis-a case report.. **2022**, 6, ytac018

169 Predicting sudden cardiac death in genetic heart disease.. **2022**, 0

168 Cardiovascular System. **2022**, 471-521

167 A Novel Mutation in the TRPM4 Gene Associated with Congenital Long QT Syndrome: A Case Report. Volume 13, 1-7

166 Clinical applicability of artificial intelligence for patients with an inherited heart disease: a scoping review.. **2022**, 0

165 Ajmaline-Induced Abnormalities in Brugada Syndrome: Evaluation With ECG Imaging.. **2022**, e024001 0

164 Gene variant effects across sodium channelopathies predict function and guide precision therapy.. **2022**, 0

163 Experiences of athletes with arrhythmogenic cardiac conditions in returning to play.. **2022**, 3, 133-140 0

162 An International Multi-Center Cohort Study on Ēblockers for the Treatment of Symptomatic Children with Catecholaminergic Polymorphic Ventricular Tachycardia. **2021**, 0

161 Monomorphic and Polymorphic Ventricular Arrhythmias in Heterozygous Calsequestrin-2 Mutation Carriers.. **2022**, CIRCGEN121003518

160 Causes of Heart Block in Young and Middle-Aged South Africans.

159 Workup for Suspected Brugada Syndrome: Two Case Reports for the General Practitioner.. **2022**, 14, e21921 0

158 Takotsubo Cardiomyopathy and Brugada Syndrome in a patient with a novel loss-of-function variant in the cardiac sodium channel Nav1.5. **2022**,

157 Longitudinal Electrocardiographic Assessment in the Brugada Syndrome. **2022**, 0

156 Salbutamol-Induced QT Interval Prolongation in a Two-Year-Old Patient.. **2022**, 14, e21904

155 Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1.. **2022**, 0

154 Stimulation cardiaque dfinitive et dfibrillation. **2021**, 161-166

153 Strategies for prevention and management of QT interval prolongation and torsades de pointes. **2022**, 303-333

152	Emerging risk factors for QT interval prolongation and torsades de pointes. **2022**, 113-156	0
151	Important unanswered research questions related to torsades de pointes. **2022**, 335-354	
150	Leitsymptom Fieber. **2022**, 255-280	
149	Grupo de trabajo sobre estimulaci□n cardiaca y terapia de resincronizaci□n cardiaca de la Sociedad Europea de Cardiologâ (ESC). **2022**,	2
148	A Survey of Immunization Practices in Patients With Congenital Heart Disease. **2022**,	
147	Approach to Wide Complex Tachycardia in Paediatric Patients. **2022**,	
146	Exome Sequencing Highlights a Potential Role for Concealed Cardiomyopathies in Youthful Sudden Cardiac Death.. **2021**, CIRCGEN121003497	0
145	Sudden Cardiac Arrest in the Paediatric Population. **2022**,	
144	Pyrexia Unmasking Brugada Syndrome: A Literature Review.. **2022**, 14, e22489	
143	Brugada Syndrome.. **2022**, 8, 386-405	2
142	Ten-year-old boy with congenital long QT syndrome type 2 (LQTS2) and life-threatening electrical storm: a case report of successful treatment with mexiletine.. **2022**, 1-2	
141	Family Screening After Sudden Death in a Population-Based Study of Children.. **2022**,	
140	[Prevention of sudden cardiac death].. **2022**, 47, 135	0
139	GENESIS: Gene-Specific Machine Learning Models for Variants of Uncertain Significance Found in Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome-Associated Genes.. **2022**, 101161CIRCEP121010326	0
138	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.	
137	Racial Disparities in Ion Channelopathies and Inherited Cardiovascular Diseases Associated With Sudden Cardiac Death.. **2022**, e023446	0
136	The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia.. **2022**, 13, 850117	
135	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. **2022**, CJ-20-1212	6

134	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.. **2022**,		5
133	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.. *Heart Rhythm*, **2022**,	6.7	6
132	Monogenic and Polygenic Contributions to QTc Prolongation in the Population.. **2022**,		0
131	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.		2
130	Using hiPSC-CMs to Examine Mechanisms of Catecholaminergic Polymorphic Ventricular Tachycardia.. **2021**, 1, e320		
129	Novel and Variants Identified in Two Unrelated Han-Chinese Patients With Clinically Suspected Brugada Syndrome.. **2021**, 8, 758903		1
128	Pediatric arrhythmology is an important direction of pediatric cardiology. **2021**, 28, 5-8		
127	A calibrated functional patch clamp assay to enhance clinical variant interpretation in KCNH2-related long QT syndrome.		
126	Magnetic resonance imaging diagnostic potential in idiopathic ventricular arrhythmias in children. **2021**, 28, 9-14		
125	Association of atrial septal defect and Brugada syndrome in a young woman.. **2021**, 1-3		0
124	Mutational Spectrum of Congenital Long QT Syndrome in Turkey; Identification of Twelve Novel Mutations Across KCNQ1, KCNH2, SCN5A, KCNJ2, CACNA1C, CALM1. **2021**,		
123	Brugada Syndrome in Women: What Do We Know After 30 Years?. **2022**, 9, 874992		0
122	Risk stratification of sudden cardiac death in Brugada syndrome: an updated review of literature.. **2022**, 74, 25		0
121	Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19.		2
120	Sex-Specific Considerations in Drug and Device Therapy of Cardiac Arrhythmias: JACC´Focus´Seminar 6/7.. **2022**, 79, 1519-1529		0
119	Research progress of Nedd4L in cardiovascular diseases.. **2022**, 8, 206		1
118	Data_Sheet_1.PDF. **2018**,		
117	Data_Sheet_2.PDF. **2018**,		

116	Table_1.doc. **2019**,		
115	Image_1.pdf. **2019**,		
114	Table_1.DOCX. **2020**,		
113	Table_1.docx. **2020**,		
112	Table_1.xlsx. **2020**,		
111	Data_Sheet_1.docx. **2019**,		
110	Efficacy and safety of catheter ablation for Brugada syndrome: an updated systematic review.. **2022**, 1		
109	Exercise Test for Patients with Long QT Syndrome.. **2022**, 38, 124-133		
108	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. **2022**, 64, 7-86		
107	ICD harm and benefit: risk scores applied to the Swedish ICD-treated LQTS population.. **2022**, 56, 48-55		
106	Contemporary Maternal and Fetal Outcomes in Treatment of LQTS during Pregnancy: Is Nadolol Bad for the Fetus?. *Heart Rhythm*, **2022**,	6.7	0
105	Analysis of site-specific late potentials using a novel Holter signal-averaged electrocardiography in patients with Brugada syndrome.. *Heart Rhythm*, **2022**,	6.7	0
104	Teenager Presenting With Chest Pain and ST-Segment Changes on Electrocardiogram After SARS-CoV-2 Illness: Early Repolarization vs. Acute Pericarditis. **2022**,		0
103	A deep learning approach identifies new ECG features in congenital long QT syndrome.. **2022**, 20, 162		0
102	Causes of Heart Block in Young and Middle-Aged South Africans.. **2022**, 101247		0
101	Sarcoplasmic Reticulum Ca Dysregulation in the Pathophysiology of Inherited Arrhythmia: An Update.. **2022**, 200, 115059		0
100	The Genetics of Brugada Syndrome.. **2022**,		0
99	Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry. **2022**, 9,		1

98	Congenital Long QT Syndrome.. **2022**, 8, 687-706		0
97	Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome. **2022**, 17, e0261390		
96	Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk. **2022**, 2, 22-45		4
95	Molecular genetic testing in athletes: Why and when a position statement from the Italian society of sports cardiology. **2022**,		0
94	Animal Models to Study Cardiac Arrhythmias. **2022**, 130, 1926-1964		4
93	Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?.		0
92	Fever following Covid-19 vaccination in subjects with Brugada syndrome: Incidence and management.		0
91	Spectrum and Prevalence of Side Effects and Complications with Guideline Directed Therapies for Congenital Long QT Syndrome. *Heart Rhythm*, **2022**,	6.7	0
90	Initiation of ventricular arrhythmia in the acquired long QT syndrome.		0
89	A calibrated functional patch-clamp assay to enhance clinical variant interpretation in KCNH2-related long QT syndrome. **2022**,		1
88	Latent Causes of Sudden Cardiac´Arrest. **2022**, 8, 806-821		0
87	Exercise in the Genetic Arrhythmia Syndromes A Review. **2022**, 41, 485-510		
86	Precision therapy in congenital long QT syndrome. **2022**,		0
85	Anesthetic Management of a Patient With Catecholaminergic Polymorphic Ventricular Tachycardia. **2022**, 69, 24-29		
84	Use of Wearable Technology and Deep´Learning to Improve the Diagnosis´of´Brugada Syndrome. **2022**,		
83	Cardiac channelopathies. **2022**,		
82	Mutation-Specific Differences in Kv7.1 (KCNQ1) and Kv11.1 (KCNH2) Channel Dysfunction and Long QT Syndrome Phenotypes. **2022**, 23, 7389		0
81	A review article of the cardiovascular sequalae in esport athletes: a cause for concern?. **2022**,		1

80	Exercise-induced arrhythmias. *Heart Rhythm*, **2022**, 19, 1214-1216	6.7
79	A massively parallel assay accurately discriminates between functionally normal and abnormal variants in a hotspot domain of KCNH2. **2022**, 109, 1208-1216	0
78	One Family's Clinical Odyssey From Evolving Phenotypic and Genotypic Knowledge of Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome. **2022**,	
77	Utility of Provocative Testing in the Diagnosis and Genotyping of Congenital Long QT Syndrome: A Systematic Review and Meta-Analysis.	
76	Novel ACTN2 missense variant is associated with idiopathic ventricular fibrillation: a case report. **2022**, 6,	
75	Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review. **2022**, 12, 1104	
74	Predictors of late arrhythmic events after generator replacement in Brugada syndrome treated with prophylactic ICD. 9,	0
73	Brugada Syndrome as a Major Cause of Sudden Cardiac Death in Asians. **2022**,	1
72	A case of long QT syndrome type 2 that developed torsades de pointes two days after the initiation of oral blocker therapy. **2022**,	0
71	Pediatric patients with Long QT Syndrome contemporary follow-up results a single-center experience. 178-187	
70	State-of-the-Art Multimodality Imaging in Sudden Cardiac Arrest with Focus on Idiopathic Ventricular Fibrillation: A Review. **2022**, 11, 4680	
69	Case report: Mexiletine suppresses ventricular arrhythmias in Andersen-Tawil syndrome. 9,	0
68	Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing.	0
67	The Outcome of Long QT Syndrome, a Korean Single Center Study. **2022**, 52, 771	1
66	Precision Medicine in Cardiovascular Disease Practice. **2022**, 53-66	0
65	The Relationship between T-Wave Alternans and Adverse Cardiac Events in Patients with Congenital Long QT Syndrome: A Systematic Review and Meta-Analysis. **2022**, 17, 557-567	0
64	The Outcome of Long QT Syndrome: What is the Optimal Therapy?. **2022**, 52, 782	0
63	Cerebral Seizures in an Adolescent with Jervell and Lange-Nielsen Syndrome: It May Not Be Epilepsy. **2022**, 12, 677-685	0

62	Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. **2022**, 13,	0
61	Moderately Prolonged QTc in Computer-Assessed ECG, Random Variation or Significant Risk Factor? A Literature Review. **2022**, 12, 261-269	0
60	Cardiogenetics: the role of genetic testing for inherited arrhythmia syndromes and sudden death. heartjnl-2021-320015	0
59	Athletic Activity for Patients With Hypertrophic Cardiomyopathy and Other Inherited Cardiovascular Diseases. **2022**, 80, 1268-1283	1
58	Microvolt T-wave alternans in early repolarization syndrome associated with ventricular arrhythmias: A case report.	0
57	Prevalence and Phenotypic Burden of Monogenic Arrhythmias Using Integration of Electronic Health Records With Genetics.	0
56	Diretriz da Sociedade Brasileira de Cardiologia sobre a An□lise e Emiss□ de Laudos Eletrocardiogr□icos □2022. **2022**,	0
55	Classic Presentation of Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report. **2022**,	0
54	A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia.	1
53	Postmortem Genetic Testing Is an Increasingly Utilized Tool in Death Investigation. 192536212211248	0
52	Rare Genetic Variants Associated with Sudden Cardiac Arrest in the Young: A Prospective, Population-Based Study.	0
51	A descriptive investigation of clinical practice models used by cardiovascular genetic counselors in North America.	0
50	Longitudinal Assessment of Structural Phenotype in Brugada Syndrome Using Cardiac Magnetic Resonance Imaging. **2022**,	0
49	Broad Electrocardiogram Syndromes Spectrum: From Common Emergencies to Particular Electrical Heart Disorders. **2022**, 12, 1754	0
48	Life-threatening cardiac arrhythmia and sudden death during electronic gaming: An international case series and systematic review. **2022**, 19, 1826-1833	0
47	Left Cardiac Sympathetic Denervation as an Acute Treatment of Torsades in a Pediatric Case of Long QT.. **2022**,	0
46	Repeatability of ventricular arrhythmia characteristics on the exercise-stress test in RYR2-mediated catecholaminergic polymorphic ventricular tachycardia.	0
45	Predictive value of the TyG index and rheumatoid factor for cardiovascular disease risk in a rheumatoid arthritis population: data from a survey of 418 patients. **2022**, 21,	0

44	Genetic concepts in inherited cardiac conditions. 1-9	1
43	Risk stratification of ventricular fibrillation in patients with symptomatic Brugada syndrome using pharmacological tests.	0
42	Next-generation sequencing of postmortem molecular markers to support for medicolegal autopsy. **2022**, 6, 100300	0
41	Attendance-related healthcare resource utilisation and costs in patients with Brugada Syndrome in Hong Kong: A retrospective cohort study. **2022**, 101513	0
40	Long QT Syndrome with Multiple Gene Mutations: A Case Report. **2022**, 12, 11123-11128	0
39	Recommendations for genetic testing and counselling after sudden cardiac death: practical aspects for Swiss practice. **2018**, 148, w14638	0
38	The Importance of Systematic Diagnostic Testing in Idiopathic Ventricular Fibrillation. **2022**,	0
37	Long QT Syndrome Management during and after Pregnancy. **2022**, 58, 1694	0
36	Inter-American Society of Cardiology (CIFACAH-ELECTROSIAC) and Latin-American Heart Rhythm Society (LAHRS): multidisciplinary review on the appropriate use of implantable cardiodefibrillator in heart failure with reduced ejection fraction.	0
35	Clinical Predictors of Pacing Device Implantation in Implantable Cardiac Monitor Recipients for Unexplained Syncope. **2022**,	0
34	Genome Editing and Inherited Cardiac Arrhythmias. **2023**, 115-127	0
33	From background to solutions: Eliminating sex gaps in clinical electrophysiology practice. **2022**, 3, 817-826	0
32	A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. **2022**, 15, 1550	0
31	Cut Left or Left Alone, What to Do in the Middle of a Storm!. **2022**,	0
30	Genome Editing and Myocardial Development. **2023**, 53-73	0
29	Sex-related differences in incidence, phenotype and risk of sudden cardiac death in inherited arrhythmia syndromes. 9,	0
28	Idiopathic Premature Ventricular Contraction (PVC) triggered Ventricular Fibrillation: subcutaneous defibrillator template matched ablation in the absence of inducible clinical PVC. **2023**,	0
27	Identification of a novel missense SCN5A mutation in a Chinese Han family with Brugada syndrome. **2023**,	0

26	Precision medicine for long QT syndrome: Patient-specific iPSCs take the lead. 1-39	0
25	Demystifying the Pediatric Electrocardiogram: Tools for the Practicing Pediatrician. **2023**, 44, 3-13	0
24	Cardiac calcium regulation in human induced pluripotent stem cell cardiomyocytes: Implications for disease modeling and maturation. 10,	0
23	The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic. **2022**, 14,	0
22	Factores asociados a la supervivencia de pacientes portadores de cardiodesfibriladores en una cohorte de Medellín, Colombia. **2022**, 33, 164-169	0
21	Risk of Sudden Infant Death Syndrome Among Siblings of Children Who Died of Sudden Infant Death Syndrome in Denmark. **2023**, 6, e2252724	0
20	Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis – 2023. **2023**, 120,	0
19	Syncope after COVID-19 Vaccination in a Young Man with Unmasking Brugada Syndrome. **2023**,	0
18	As Cinco Ondas Malignas da Eletrocardiografia. **2023**, 120,	0
17	Management of Inherited Arrhythmia Syndromes: A HiRO Consensus Handbook on Process of Care. **2023**, 5, 268-284	0
16	Whole-exome sequencing and electrophysiological study reveal a novel loss-of-function mutation of KCNA10 in epinephrine provoked long QT syndrome with familial history of sudden cardiac death. **2023**, 62, 102245	0
15	The eSports Medicine: Pre-Participation Screening and Injuries Management – An Update. **2023**, 11, 34	0
14	Calcium Handling in Inherited Cardiac Diseases: A Focus on Catecholaminergic Polymorphic Ventricular Tachycardia and Hypertrophic Cardiomyopathy. **2023**, 24, 3365	0
13	Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification. **2023**, 24, 3328	0
12	Sudden Cardiac Death Risk Stratification of the Early Repolarization Syndrome: An Updated Review of the Literature. **2023**, 25, 203-212	0
11	Whole-exome sequencing: Clinical characterization of pediatric and adult Italian patients affected by different forms of hereditary cardiovascular diseases.	0
10	Frontier and hotspot evolution in Brugada syndrome: A bibliometric analysis from 2002 to 2022. **2023**, 102, e33038	0
9	COVID -19-associated Brugada pattern electrocardiogram: Systematic review of case reports.	0

8	Opportunities and drawbacks of the subcutaneous defibrillator across different clinical settings. **2023**, 21, 151-164	0
7	The role of DNA-profiling in predicting anticonvulsant-induced QT prolongation diseases based on pharmacogenetic aspects. **2023**, 37-52	0
6	Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell□Derived Cardiomyocytes. **2023**, 16,	0
5	Bilateral cardiac sympathetic denervation in patients with congenital long QT syndrome. **2023**,	0
4	Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart Association. **2023**, 16,	0
3	□It□s Overwhelming With the Grief□A Qualitative Study of Families□Experiences When a Young Relative Dies of Sudden Cardiac Death. **2023**, 16,	0
2	The safety of sports in children with inherited arrhythmia substrates. 11,	0
1	Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor. Publish Ahead of Print,	0